==== Front Healthcare (Basel) Healthcare (Basel) healthcare Healthcare 2227-9032 MDPI 33019579 10.3390/healthcare8040378 healthcare-08-00378 Review Exercise-Induced Myokines can Explain the Importance of Physical Activity in the Elderly: An Overview Kwon Jenny Hyosun 1 Moon Kyoung Min 2* https://orcid.org/0000-0002-4757-9211Min Kyueng-Whan 3 1 Department of Kinesiology, Indiana University, Bloomington, IN 47405, USA; jenkwon@iu.edu 2 Department of Pulmonary, Allergy, and Critical Care Medicine, GangNeung Asan Hospital, University of Ulsan College of Medicine, Gangneung 25440, Korea 3 Department of Pathology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri 11923, Korea; kyueng@gmail.com * Correspondence: pulmogicu@ulsan.ac.kr 01 10 2020 12 2020 8 4 37809 9 2020 27 9 2020 © 2020 by the authors.2020Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).Physical activity has been found to aid the maintenance of health in the elderly. Exercise-induced skeletal muscle contractions lead to the production and secretion of many small proteins and proteoglycan peptides called myokines. Thus, studies on myokines are necessary for ensuring the maintenance of skeletal muscle health in the elderly. This review summarizes 13 myokines regulated by physical activity that are affected by aging and aims to understand their potential roles in metabolic diseases. We categorized myokines into two groups based on regulation by aerobic and anaerobic exercise. With aging, the secretion of apelin, β-aminoisobutyric acid (BAIBA), bone morphogenetic protein 7 (BMP-7), decorin, insulin-like growth factor 1 (IGF-1), interleukin-15 (IL-15), irisin, stromal cell-derived factor 1 (SDF-1), sestrin, secreted protein acidic rich in cysteine (SPARC), and vascular endothelial growth factor A (VEGF-A) decreased, while that of IL-6 and myostatin increased. Aerobic exercise upregulates apelin, BAIBA, IL-15, IL-6, irisin, SDF-1, sestrin, SPARC, and VEGF-A expression, while anaerobic exercise upregulates BMP-7, decorin, IGF-1, IL-15, IL-6, irisin, and VEGF-A expression. Myostatin is downregulated by both aerobic and anaerobic exercise. This review provides a rationale for developing exercise programs or interventions that maintain a balance between aerobic and anaerobic exercise in the elderly. myokineelderlyexercisephysical activityaerobicanaerobic ==== Body 1. Introduction Owing to the improvements in healthcare and nutrition, life expectancy is increasing rapidly across the globe. It has been estimated that the elderly population, i.e., people over 60, will have increased by over 200% between 1970 and 2025 [1]. With the continued increase in life expectancy, health problems that afflict the elderly have garnered much attention. The prevalence of chronic diseases, such as diabetes, cancers, and cardiovascular, respiratory, and arthritic diseases, is increasing as the aging of the global population accelerates [2,3]. Skeletal muscle loss is among the most serious physical changes that the elderly experience. Approximately 75% of the individuals over 65 years of age do not indulge in the minimum physical activity required to stay healthy [4]. Skeletal muscle loss is a major health hazard as it is causally related to sarcopenia [5]. This muscular atrophy is associated with the development of sarcopenia, which is defined as a progressive decline in skeletal muscle mass and strength without loss of overall body weight that occurs with aging [6]. Individuals who spend much time sitting are prone to muscle mass loss and weakness, and therefore, they are at higher risk of developing sarcopenia [7]. In 1931, Critchley first recognized that the intrinsic mass of the hand and foot muscles decreased with aging [8]. Muscle weakness and decreased muscle mass negatively affect the elderly, both physiologically and psycho-socially, as they cause difficulty in performing daily tasks, increasing the risk of falling, reducing independence and quality of life, and increasing depression, social isolation, physical inactivity (sedentarism), susceptibility to chronic diseases, and rates of all-cause mortality [9,10,11]. The World Health Organization (WHO) announced that physical inactivity (5.5% of the total or 3.2 million) is the fourth most serious global health risk associated with mortality following high blood pressure, tobacco use, and high blood glucose [12]. Skeletal muscles are attached to bones by tendons and aponeuroses and are under the voluntary control of the somatic nervous system. They account for 30–50% of the total body mass and are primarily responsible for locomotion and metabolic homeostasis [13]. In recent decades, it has been discovered that contracting skeletal muscles release various hormone-like substances [14,15]. These activators are called myokines, which are small proteins (5–20 kDa) and proteoglycan peptides that are produced and secreted by skeletal muscle cells in response to muscle contractions [16,17]. Early in the study of myokines, it was hypothesized that high levels of exercise-induced circulating cytokine IL-6 released by immune cells (NK cells and CD8+ cells) were associated with muscle damage [18]. Although the plasma IL-6 concentration increases approximately 100-fold after exercise, it normalizes rapidly [19]. Electric stimulation inducing the rat gastrocnemius and soleus muscles produced contraction without injury and resulted in increased IL-6 [20]. Furthermore, in humans, the IL-6 turnover in the femoral arteries and veins has been demonstrated to be very sensitive to muscle exercise [21]. These results suggest that skeletal muscle contraction is associated with IL-6 secretion. However, it remains possible that free macrophages in the blood enter the skeletal muscle and secrete IL-6 during muscle contractions. Recently, with the development of molecular analysis techniques, such as quantitative real-time PCR and a new contractile C2C12 myotube model, it has been directly demonstrated that IL-6 is secreted by skeletal muscles [22,23,24,25]. Various myokines secreted by skeletal muscles during aerobic and anaerobic exercises have been studied in connection with various human diseases using state-of-the-art techniques, including total RNA sequencing [26,27,28]. For a long time, skeletal muscles were only recognized as being involved in the physical aspects of exercise. However, with the discovery of exercise-induced myokines, skeletal muscles have been demonstrated to be involved in the maintenance of metabolic homeostasis. Although the detailed mechanisms are not clear, both skeletal muscle contraction and mass maintenance appear to be actively involved in maintaining health and preventing disease development in the elderly, particularly considering the rapid deterioration of muscle physiology with aging. Thus, studies on myokines are necessary for ensuring the maintenance of skeletal muscle health in the elderly. This review summarizes the myokines regulated by physical activity that are affected by aging and aims to understand their potential roles in metabolic diseases. We have reviewed 13 myokines whose secretion is influenced by aging but controlled by physical activity. We categorized these myokines into two groups, one regulated by aerobic exercise and the other by anaerobic exercise. With aging, the secretion of apelin, BAIBA, BMP-7, decorin, IGF-1, IL-15, irisin, SDF-1, sestrin, SPARC, and VEGF-A decreased, while that of IL-6 and myostatin increased. Aerobic exercise upregulates apelin, BAIBA, IL-15, IL-6, irisin, SDF-1, sestrin, SPARC, and VEGF-A expression, while anaerobic exercise upregulates BMP-7, decorin, IGF-1, IL-15, IL-6, irisin, and VEGF-A expression. Myostatin is downregulated by both aerobic and anaerobic exercise. 2. Myokines 2.1. Apelin Human apelin was identified and isolated in 1998 as an endogenous ligand of the G-protein-coupled receptor APJ and was named the APJ endogenous ligand. The apelin gene located at chromosome Xq25–26.1, encodes a 77 amino acid preproprotein [29,30]. After the cleavage of the signal peptide, the protein is processed into various bioactive endogenous peptides, such as apelin-13, -16, -17, and -36 [31], which are widely expressed in various organs. Apelin regulates a wide range of physiological processes, including blood pressure [32], cardiac contractility [33], and angiogenesis [34], and is involved in pathophysiological processes underlying hypoxia [35], obesity [36], diabetes [37], and various cancers [38]. In one study, myokine expression in the vastus lateralis was examined in 11 obese nondiabetic males after cycling and running (aerobic exercise) for 8 weeks; in contrast to what is known for the other known myokines, this study reported a significant increase in the expression and secretion of apelin. This was the first study to recognize apelin as a myokine [39]. A reduction in apelin has also been observed in elderly subjects. In particular, abnormalities in muscle function grow more severe with age in apelin (-/-) mice. Thus, apelin has been suggested as a biomarker for diagnosing early sarcopenia and a target for the development of therapeutic agents for age-associated muscle weakness [40]. Also, Rai et al. showed that the downregulation of the apelinergic axis accelerated the onset and progression of aging [41]. The concentration of plasma apelin increases in response to aerobic exercise. Apelin mRNA expression increased by approximately 40% in hypertensive rats in response to swimming training for 9 weeks, and had positive effects on hypertension [42]. Apelin mRNA expression in the vastus lateralis was upregulated 3.3-fold after 11 obese males were subjected to aerobic exercise (cycling and running) for 8 weeks [39]. Skeletal muscle from mice subjected to aerobic exercise (treadmill and ladder) and C2C12 cells treated with the exercise mimetic, forskolin showed increased apelin plasma and mRNA concentrations, respectively [43]. Furthermore, a combination of apelin treatment and exercise (treadmill) significantly reduces ischemia-reperfusion injury in rats [44]. 2.2. β-aminoisobutyric Acid (BAIBA) BAIBA (C4H9NO2) is a small, non-protein myokine with a molecular weight of 103.6 Da that was first discovered in human urine in 1951 [45]. It is secreted by contracting muscles via the action of peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) and acts in a myokine-specific manner [46,47]. It is involved in various metabolic processes, such as acting on white adipose tissue to upregulate brown adipose tissue-specific genes, enhancing PGC-1α expression to increase lipid oxidation, suppressing inflammation in skeletal muscles, inhibiting cardiometabolic risk factors, and suppressing endoplasmic reticulum stress in hepatoblastoma cells. Blood BAIBA levels increase in response to continuous exercise [46,48,49,50]. The myokine properties of BAIBA suggest that many small molecule metabolites may have myokine functions. Although its various functions are known, few studies have investigated the function of BAIBA in aging skeletal muscles. Plasma BAIBA levels are higher in young subjects than those in the elderly [51]. This could be because BAIBA expression is regulated by PGC-1α, and PGC-1α expression is lower in elderly subjects than that in young subjects [52,53]. This difference in PGC-1α expression is considered to be aging-dependent during acute exercise. BAIBA secretion is unchanged in young and old muscle; however, the expression of its receptor (Mas-related G-protein receptor Type D) decreases markedly in an age-dependent manner in osteocytes [54,55,56]. Secretion of BAIBA by skeletal muscles increases in mice overexpressing PGC-1α. Additionally, high plasma BAIBA concentrations are observed in humans undergoing wheel-running exercise but are inversely correlated with metabolic risk factors, which suggests that BAIBA may protect against metabolic diseases [46,57,58,59]. In one study, blood BAIBA levels were measured after 16 weeks of aerobic exercise training in Native American boys and girls (11–17 years) divided into obese and normal-weight groups. Individuals in the normal-weight group had 29% higher BAIBA levels than those in the obese group [60]. Physical inactivity in patients on hemodialysis reduces plasma BAIBA concentrations [61,62]. Kitase et al. reported that BAIBA functions as an osteocyte survival factor, protects against mitochondrial degradation due to ROS (reactive oxygen species), and regulates bone and skeletal muscle loss due to aging [54]. These results indicate that BAIBA is an important regulator of metabolic activity and is affected by a lack of exercise, which is frequently seen in the elderly. 2.3. Bone Morphogenetic Protein 7 (BMP-7) In 1965, Urist recognized BMP as an important factor in osteogenesis and bone formation [63]. BMP-7, also called osteogenic protein-1, is a member of the TGF-β superfamily of cysteine-knot fold cytokine-growth factors [64]. Human BMP-7 has been isolated and mapped to chromosome 20q13.31. This has been proposed as a possible locus for the Holt-Oram syndrome, which manifests as skeletal abnormalities of the upper limbs and hands [65,66,67]. BMP-7 is a multifunctional growth factor involved in cell proliferation, apoptosis, organ repair, and differentiation of brown adipose tissue, but its most important function is inducing cartilage and bone formation [68,69,70,71]. BMP-7 mRNA and protein levels are lower in elderly subjects, in both humans and rats, compared to young ones [72,73]. BMP-7 mRNA and protein are also expressed at low levels in articular cartilage of elderly subjects with osteoarthritis [74] owing to methylation of the BMP-7 promoter [75]. BMP-7 induces myotube formation in the mouse pluripotent mesenchymal precursor cell line C2C12 and causes increased expression of muscle differentiation factors such as BMP-1, GDF-6, and GDF-8 [76]. Winbanks et al. demonstrated that BMP-7 is a positive regulator of skeletal muscle mass in a neurogenic atrophy model [77]. Biomechanical stimulation (1 Hz for 3 h/day) increased BMP-7 mRNA expression in rat osteoblasts and inhibited posttraumatic osteoarthritis [78]. Expression of BMP-7 mRNA and protein increased in the gastrocnemius and lower limbs skeletal muscles of rats (rectus femoris, vastus lateralis, and gastrocnemius) after endurance training and gradual exercise, respectively [73,79]. 2.4. Decorin Human decorin is a small leucine-rich proteoglycan of 90–140 kDa that is associated with collagen fibrils in all connective tissue. The gene is located on chromosome 12q23 [80] and regulates transforming growth factor (TGF)-beta 1 activity as well as the cell cycle [81]. Decorin suppresses myostatin activity, which is associated with obesity and diabetes [47]. In 2014, decorin was first recognized as a myokine, and its levels in both plasma and skeletal muscle increase in response to physical activity [82]. A study that compared young (0–15 years) and old (16–83 years) individuals demonstrated that decorin mRNA expression decreases significantly in an age-dependent manner in human skin fibroblast [83]. In one study, the molecular weight of decorin isolated from the placenta of an old rat was estimated to be approximately 40 kDa, which is smaller than that of the normal protein (approximately 100 kDa). The smaller size was attributed to variations in the glycosaminoglycan base structure with aging [84]. Age-dependent changes in decorin have also been observed in human skin [85]. Although tendon injuries occur very frequently in the elderly, few studies have investigated the relationship between decorin and aging tendons. Dunkman et al. reported that decorin expression is closely related to the changes in aging tendons [86,87]. Articular cartilage decorin levels increase in beagle dogs after long-distance running exercise (40 km/day, 15 weeks) [88]. In 31 young men, decorin mRNA in the vastus lateralis, but not that in the patellar tendon, increased after exercise on a Krogh ergometer [89]. Anaerobic exercise upregulates decorin levels in the human plasma and decorin mRNA in the vastus lateralis, and regulates the expression of genes coding for proteins, such as follistatin, Myod1, atrogin1, and MuRF1, which are involved in hypertrophic pathways in the skeletal muscle [82]. When rats were subjected to moderate exercise on a treadmill, the expression of decorin at mRNA and protein levels increased, whereas they decreased in the calcaneal tendon during strenuous treadmill running. Increased decorin levels regulate matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in the surrounding tissue, which makes the tendon stronger [90]. 2.5. Insulin-Like Growth Factor 1 (IGF-1) In 1957, IGF-1 was first recognized by Salmon and Daughaday as a “sulfation factor” that stimulates sulfate incorporation in rat cartilage [91]. In 1978, Rinderknecht and Humbel purified a human IGF-1, a protein of 70 amino acids with structural resemblance to proinsulin [92]. In 1983, the human IGF-1 cDNA was cloned, and in 1984, IGF-1 was found to be located on chromosome 12q23.2 [93,94]. Although IGF-1 is a multifunctional peptide, its main physiological function is as a growth hormone (GH) essential for normal bone and tissue growth and development [95]. In 2012, IGF-1 was recognized as a myokine produced and secreted by the muscle fibers [96]. Plasma IGF-1 decreases with age in humans, leading to GH release impairment, immunocompetence, and GH-IGF axis activity [97,98,99,100,101]. Furthermore, DNA synthesis and proliferation are observed in response to aging-associated low IGF-1 levels [102,103]. IGF-1 gene-ablated (IGF-1-/-) mice are characterized by severely impaired health [104] and poor mitochondrial function in the hippocampus [105]. IGF-1 levels have been reported to be low in community-dwelling elderly subjects and shows promise as a biomarker for sarcopenia [106,107]. Several studies have shown that impaired IGF-1 activity results in muscular dysfunction. Elderly marathon runners have high GH-IGF activity, which indicates that exercise in the elderly is closely related to IGF-1 activity [108]. IGF-1 is upregulated in response to anaerobic exercise, such as weightlifting in 72- to 98-year-old women [109]. Additionally, rats with spinal cord injury exhibited IGF-1 upregulation in the soleus after treadmill training, which resulted in the upregulation of muscle regeneration markers, such as myogenin and MyoD [110]. Significantly increased IGF-1 mRNA expression has been reported in postmenopausal women after a single-leg extension exercise [111]. 2.6. Interleukin-15 (IL-15) Human IL-15 was reported simultaneously by two groups in 1994 as a T-cell growth factor. IL-15, located on chromosome 4q31, encodes a 14–15 kDa glycoprotein incorporating a four α-helix bundle [112,113,114]. In humans, IL-15 expression is detected in various cells and tissues, including skeletal muscle, epithelial cells, monocytes, and dendritic cells [115]. The primary biological functions of IL-15 are to activate and proliferate T-cells and NK cells, inhibit apoptosis, and accelerate CD8(+) antitumor immunity [116,117,118]. Brandt and Pedersen suggested in 2010 that muscle-derived IL-15 is a myokine constitutively expressed by skeletal muscles and is regulated in response to strength training [119]. The levels of plasma IL-15, quadriceps IL-15, and gastrocnemius IL-15 decline gradually with age in rodents [120,121]. Plasma IL-15 levels also decrease with age in humans [122]. Elderly subjects with sarcopenia have significantly lower plasma IL-15 levels, and studies have reported a relationship between sarcopenia and insufficient plasma IL-15 levels [123,124]. Age-dependent upregulation of IL-15 has been reported in splenic stromal cells but not in skeletal muscle [125]. Several studies have shown that exercise upregulates plasma IL-15 levels as well as IL-15 mRNA and protein levels in skeletal muscle. In one study, a noticeable increase in plasma IL-15 levels was observed in 76 men and 77 women after 10 weeks of weight training (i.e., chest press, seated row, hamstring curl, incline press) [126]. Pérez-López et al. reported a significant increase in plasma IL-15 levels and muscle IL-15 mRNA and protein levels after leg press and knee extension resistance exercises [127]. In rats with type 2 diabetes, the expression of IL-15 protein increased significantly in the soleus after 12 weeks of aerobic exercise (treadmill training) [128] and increased by 40% in the vastus lateralis of 30 men after 12 weeks of endurance exercise on a cycloergometer [129]. Upregulation of IL-15 after treadmill running increases fibroblast collagen synthesis and cell proliferation via the AMPK—Activated Protein Kinase, signaling pathway [122]. Hingorjo et al. demonstrated a twofold increase in plasma IL-15 levels after a single session of submaximal aerobic exercise [130]. Plasma IL-15 levels more than doubled in 37 athletes (11 females and 26 males) who performed acute long-distance (35 km) endurance exercise [131]. 2.7. Interleukin-6 (IL-6) IL-6 is a cytokine that plays multifunctional roles in the regulation of the immune system, nervous system, and glucose homeostasis [132,133]. IL-6 has several names, including interferon beta-2 (IFNB2), B-cell stimulatory factor 2 (BSF2), hepatocyte stimulatory factor, and hybridoma growth factor. Zilberstein et al. and Hirano et al. cloned full-length cDNAs encoding human IFNB2—a 23.7 kDa protein comprising 212 amino acids—and human BSF2—a novel interleukin comprising 184 amino acids—respectively [134,135]. Using in situ hybridization, Sutherland et al. identified that IFNB2 is located on chromosome 7p15.3 [136]. The extramembrane (IL-6r) and intramembrane (gp130) domains of the IL-6 receptor were cloned in 1988 and 1990, respectively [137,138]. IL-6 is the first myokine produced and released into the supernatant when C2C12 myotubes and skeletal muscle fibers are induced to contract by electrical pulse stimulation [22,23]. Plasma IL-6 levels are relatively higher in elderly subjects compared to those in younger subjects, particularly in men [139]. Many studies have reported that plasma IL-6 levels increase with age [140,141,142,143]. Although the mechanism underlying age-related IL-6 upregulation is not fully understood, increases in IL-6 levels affect redox balance, mitochondrial physiology, and satellite cells in skeletal muscle [144,145,146]. Further studies are required to investigate sgp130 and sIL-6r expression, which is not always consistent with the increase in plasma IL-6 levels during aging. IL-6 levels increase in urine, but not in plasma, after long-distance running [147]. Steensberg et al. demonstrated that plasma IL-6 levels increase with exercise, which contribute to the maintenance of glucose homeostasis [21]. Since then, many studies have reported increased IL-6 levels in response to exercise. IL-6 mRNA levels increased significantly after a single round of exercise in an in vitro exercise model employing human cultured vastus lateralis cells [148]. However, plasma IL-6 did not change in patients with progressive multiple sclerosis after acute endurance exercise (i.e., arm ergometry, rowing, and bicycle ergometry) [149]. These results indicate that the effects of exercise on IL-6 differ in healthy subjects and in diseased patients, which should be considered in future studies. No changes in baseline IL-6 levels, or those observed in response to different intensities of isovolumetric resistance exercise were observed in a study of elderly (≥65 years) men [150]. Furthermore, blood-flow-restricted resistance exercise does not regulate IL-6 expression [151]. In one study, IL-6 mRNA expression increased significantly in healthy men (20.5 ± 1.5 years) after high-intensity interval training [152]. In another study, patients with a spinal cord injury developed muscle atrophy and sympathetic nervous system dysfunction owing to the lack of an exercise-related IL-6 response [133]. Finally, IL-6 levels increased after acute strenuous exercise, i.e., a wheelchair marathon [153,154]. A recent study showed that plasma IL-6 levels are closely related to obesity, microglial function, and lactate production [155,156,157]. Pedersen et al. have published several studies on the relationship between exercise and IL-6 levels in great detail [19,158,159]. 2.8. Irisin (Fibronectin Type III Domain Containing 5 [FNDC5]) Irisin, which is a novel myokine discovered in 2012, is expressed in a PGC-1α-dependent manner to produce FNDC5. This is followed by cleavage of the N-terminal signal peptide and C-terminal hydrophobic domain, resulting in the production of a 12 kDa glycoprotein that is secreted into the bloodstream and is involved in fat metabolism. FNDC5 is predominantly localized in the endoplasmic reticulum [160]. Genomic sequencing analyses indicate that FNDC5 contains six exons and this gene has been mapped to chromosome 1p35.1 [161]. Although the irisin receptor is unknown, irisin is highly conserved in all mammalian species, which suggests highly conserved biological functions [162]. Recently, irisin has been hypothesized to be involved in the downregulation of insulin resistance pathway (ROS → p38 MAPK → PGC-1α → irisin → insulin resistance pathway), which is positively controlled by exercise and negatively controlled by aging [163]. Baseline circulating irisin levels are lower in older than in younger subjects [164]. When plasma irisin concentrations were measured in 715 Korean participants divided into three groups (40s, 50s, and 60s), the lowest concentrations were found in the oldest group [165]. Irisin mRNA expression is significantly lower in old rats with acute liver injury than that in young rats [166]. However, unlike plasma irisin, irisin in the cerebrospinal fluid of humans has been demonstrated to increase with age [167], and the shortening of telomere length with aging is negatively correlated with plasma irisin levels [168]. Aerobic exercise, such as running, swimming, and treadmill training, upregulates the expression of irisin at mRNA and protein levels, as well as irisin levels in the plasma, in humans, mice, and rats [169,170,171,172,173,174,175,176,177]. However, irisin production is higher in cardiac muscle than that in skeletal muscle, which suggests that skeletal muscle is probably not the main source of irisin. Therefore, it is necessary to accurately evaluate how much plasma irisin is secreted from the skeletal muscles [178]. Bubak et al. reported that temperature (33 °C or 7 °C) during exercise does not affect plasma irisin concentrations, and Fox et al. demonstrated that exercise increases plasma irisin concentrations [179,180]. Furthermore, the increase in irisin levels in response to exercise ameliorates the functional impairment of neurons, which suggests the possibility of treating Alzheimer’s disease [181,182,183]. 2.9. Myostatin (Growth/Differentiation Factor-8 [GDF-8]) Myostatin (GDF-8), a member of the TGF-β superfamily, plays an important role in the negative regulation of skeletal muscle growth and is specifically expressed in developmental and adult skeletal muscle [184,185]. Myostatin, inhibited by follistatin, has recently attracted attention as a useful pharmacological target for preserving muscle mass and preventing atrophy [186]. McPherron et al. and Gonzalez-Cadavid et al. isolated and characterized the mouse myostatin and human myostatin genes, respectively [184,187]. In one study, plasma myostatin concentration in three groups of subjects (19–35, 60–75, and 76–92 years) were highest in the 76–92-year-old group, which suggests that plasma myostatin could be used as a biomarker for diagnosing age-associated sarcopenia [188]. Resistance training decreases plasma myostatin concentrations in healthy men, and acute resistance exercise decreases myostatin signaling by activating Notch signaling in rats [189,190]. Myostatin mRNA and plasma protein levels in rat decrease in response to aerobic exercise, and the same results have been reported in humans [191,192,193,194]. Patients with chronic heart failure show an increase in myostatin mRNA and protein; however, they decrease with exercise, indicating a beneficial anti-catabolic effect in patients with chronic heart failure [195,196]. The same result has been observed in patients with chronic kidney disease [197,198]. A combination of myostatin inhibition and endurance training is particularly effective for treating lipidomic abnormalities [199]. In some cases, different results have been reported depending on age, sex, exercise type (aerobic or anaerobic), and localization (plasma or muscle). The complex in vivo roles of myostatin have been studied and speculated upon [107,200,201,202,203], and it is an interesting target candidate for further research. 2.10. Stromal Cell-Derived Factor 1 (SDF-1) The expression of SDF-1—also called CXC motif chemokine ligand 12 (CXCL12), intercrine reduced in hepatomas (IRH), and pre-B cell growth-stimulating factor—is expressed in many cell types (i.e., fibroblasts, myoblasts, muscle fibers) [204]. This chemokine was originally described as a B-cell precursor stimulating growth factor secreted by a bone marrow stromal cell line [205]. CXCR4 and CXCR7 are the primary physiological receptors of SDF-1 [206,207], and the gene coding for this protein is located on chromosome 10q11.1 [208,209]. SDF-1-CXCR4 signaling occurs in the mesenchyme of limbs during early development and is directly responsible for the development of appropriately sized muscles [210], which indicates its important role in skeletal muscle regeneration [211,212]. Alzheimer’s disease (AD) is the most common form of dementia in the elderly. The Tg2576 mouse model of AD, in which the gene encoding human amyloid precursor protein is expressed, is an important AD animal model. CXCL12 levels are lower in AD patients compared to those in heathy controls, which suggests that CXCL12 is closely associated with aging [213]. The numbers of senescent fibroblasts increase in aged pigmented skin, where SDF-1 mRNA expression is reduced 3.55-fold [214]. SDF-1 expression is downregulated in the wounded skin of old mice, just as it is suppressed in an age-dependent manner in human skin [215]. Periyasamy-Thandavan et al. reported decreases in SDF-1 concentrations and bioactivity in the bone marrow interstitial fluid of older humans (18–40 vs. 60–85 years) and mice (3 vs. 22 months) [216]. SDF-1 expression is negatively regulated by miR-141–3p in an age-dependent manner [216]. The concentration of plasma CXCL12 is enhanced in response to training on a bicycle ergometer [217], and rounds of acute exercise increase CXCL12 mRNA expression in the skeletal muscle [218]. Four weeks of treadmill running produced a 3-fold increase in CXCL12 mRNA and protein levels in the gastrocnemius of rats, which activated mTOR-p70S6K signaling to induce autophagy [219]. When C2C12 myotubes are mechanically stretched, CXCL12 production and release increase results in the activation of endothelial cell proliferation. CXCL12 KO (CXCL12-/-) mice suffer from severely impaired angiogenesis in skeletal muscles [220]. 2.11. Sestrin Sestrin was first discovered in 1994 as a target of the tumor suppressor p53 and was referred to as p53-activated gene 26 (PA26). The gene coding for sestrin is located on chromosome 6q21 [221,222]. In mammalian cells, three different sestrin isoforms, which share high sequence homology, are encoded by genes located on different chromosomes, Sestrin1 on chromosome 6, Sestrin2 on chromosome 1, and Sestrin3 on chromosome 11 [223]. Sestrin acts as an intracellular leucine sensor to negatively regulate the target of rapamycin complex 1 (TORC-1) signaling by activating AMP-dependent protein kinase (AMPK), which prevents the development of sarcopenia and extends the life span [224]. Pathophysiological stressors, such as DNA damage and oxidative stress, upregulate sestrin expression, which negatively regulates aging by activating the AMPK/autophagy pathway and inhibiting the TORC1 signaling [225]. Sestrin2 is downregulated in the gastrocnemius muscle of old mice, which is characterized by a marginal reduction in sestrin2 mRNA and a significant reduction in sestrin2 protein [226]. The expression of cardiac sestrin2 also decreases with age [227]. In a study of 31 young (18–30 years) and 73 older (65–80 years) men without specific diseases in New Zealand and Australia, plasma sestrin1 and sestrin3 levels were found to decrease with age [228]. Rai et al. reported that concentrations of plasma sestrin1 and sestrin2 decrease significantly in elderly subjects [229]. An early study on Drosophila sestrin showed that inactivation of sestrin results in a significant increase in the development of age-associated pathologies, such as cancer, diabetes, muscle dystrophy, and chronic inflammation [230]. mRNA expression and plasma and skeletal muscle levels of sestrin1 and sestrin2 increase simultaneously after exercise [231]. Sestrin2 protein expression increases in response to aerobic exercise (i.e., swimming) in old mice [226]. Phosphorylation of sestrin2 in response to exercise induces p62 dephosphorylation, thereby inducing oxidative stress and selective autophagy [232]. Exercise-induced sestrin has been demonstrated to interact with AMPK, although the precise molecular mechanism remains unclear. Thus, sestrin is beneficial and may provide new insight into age-associated metabolic diseases [233,234,235]. 2.12. Secreted Protein, Acidic, Rich in Cysteine (SPARC; Osteonectin/Basement-Membrane Protein 40) In 1989, the human SPARC was first demonstrated to be located on chromosome 5q33.1 [236], and since then, it has been confirmed that the SPARC protein functions in a Ca2+-ion-dependent manner [237]. SPARC is a 43 kDa secretory matricellular glycoprotein that has multiple biological functions, including tumor-suppressing activity, cell differentiation, and cell adhesion in several organs and cell types [238,239,240]. SPARC was first recognized as a myokine in 2013 as a result of cell-stretching stimulation experiments on C2C12 myocytes [241]. In experiments on young (4–5 months) and old (>21 months) male rats, SPARC expression unchanged in skeletal muscle progenitor cells of the old rats, whereas SPARC protein expression decreased in the same rats [242]. Silencing of SPARC using siRNA led to a direct reduction in myofibril diameter. Therefore, age-related decreased expression of SPARC may induce sarcopenia development [243,244]. Other studies have reported that SPARC expression generally decreases with age (7–10 vs. 24–30 weeks) in the tibialis anterior of wild mice [245]. In 2013, it was first demonstrated experimentally that aerobic exercise (i.e., cycling) increases SPARC secretion twofold in human plasma, and the same result was obtained in C2C12 myoblasts stimulated with electric pulses [241]. Catoire et al. identified SPARC as a myokine whose expression is upregulated in response to acute exercise [246]. It has been suggested that SPARC is a tumor suppressor, as changes in SPARC expression affect sensitivity to radiation and chemotherapy in patients with colorectal cancer [247,248]. It has recently been reported that exercise-induced SPARC expression suppresses cancer, as azoxymethane (AOM)-induced colonic tumorigenesis is inhibited by exercise, but not in SPARC(-/-) mice [241]. However, plasma SPARC levels do not increase in response to a single brief supramaximal cycle sprint, which suggests that the SPARC in the plasma originates from organs other than skeletal muscle, so the origin of SPARC in the blood must be clarified [249]. However, SPARC has gained attention as a myokine because of its cancer-suppressing effects [250]. 2.13. Vascular Endothelial Growth Factor A (VEGF-A) VEGF-A, first discovered in 1983 [251], is encoded by a gene located on chromosome 6p21.1; the cDNA encoding VEGF-A was isolated in 1989 [252]. VEGF-A is a secreted, 46 kDa homodimer glycoprotein containing a highly conserved receptor-binding cysteine-knot structure. VEGF-A is one of the most important factors in the growth and survival of skeletal muscle in humans and animals [253]. We conducted a bibliographic search on whether physical exercise affects plasma VEGF-A concentration in the elderly; we referred to the 10 most relevant (of the 574) articles published between 1990 and 2013. Although four articles confirmed increases in plasma VEGF-A concentration after physical exercise, the other six articles found no changes [254]. The downregulation of VEGF-A mRNA and protein expression has been reported in aged human dermal microvascular endothelial cells [255] and in aged skeletal muscle obtained from the human vastus lateralis [256]. Experiments using VEGF-A KO (VEGF-/-) mice have revealed reduced gastrocnemius muscle mass (by 80–90%) [257]. However, various studies have shown that physical exercise upregulates VEGF-A. VEGF-A mRNA and protein levels increased twofold in skeletal muscle after one-legged knee extension training (anaerobic exercise) for 8 weeks in patients with heart failure [258]. The increase in reactive oxygen species (ROS) due to exercise increases the expression of PGC-1α, resulting in upregulation of VEGF-A expression in skeletal muscle [259]. In one study, when mice were made to run on wheels (aerobic exercise) for 14 days, VEGF-A expression increased by 34.6% in the skeletal plantaris, but VEGF-/- mice did not recover after exercise training [260]. 3. Discussion The most reasonable way to maintain healthy muscles is to increase muscle mass through appropriate physical exercise and leisure-time physical activity (LTPA), such as walking, dancing, gardening, hiking, and swimming. Many recent studies have proved that maintaining high-quality muscles through appropriate physical activity helps prolong life via various mechanisms [261,262]. Many studies have demonstrated the beneficial effects of physical activity on the physical health of the elderly as a solution for preventing aging-related diseases [263,264,265,266]. Generally, exercise burns fat, preventing the accumulation of fat in the body. This reduces the likelihood that controlling metabolic risk factors such as high triglyceride, low high-density lipoprotein (HDL) cholesterol level, and high blood pressure would result in reduced incidence of metabolic diseases to which the elderly are vulnerable. Many studies have demonstrated that physical activity prevents metabolic diseases and contributes to a prolonged life span [261,262]. Physical exercise enhances immunity and improves memory, which is beneficial in Alzheimer’s disease [267,268]. LTPA also decreases the risks of 13 types of cancer [269]. Maintaining the thigh circumference, a typical skeletal muscle, reduces the risks of developing heart disease and premature death [270]. Indeed, physically active people are at a lower risk of all-cause mortality than their physically inactive counterparts [271]. In line with previous research, many experimental studies have proved the positive impact of physical activity on cognitive ability in the elderly [272,273,274]. Overall, physical activity has a direct positive effect on maintaining the health of the elderly. The biggest takeaway of our review is that both aerobic and anaerobic exercises exert positive effects on skeletal muscles by releasing various myokines that are beneficial to the elderly. Given that most studies on LTPA in the elderly have focused on aerobic exercises [275,276,277], it is worth broadening the scope of research by examining the need for anaerobic exercise. The incidence of typical muscle diseases in the elderly could be attributed to normal food intake without ATP production in the body, which results in an age-related decline in skeletal muscle mass and strength (sarcopenia). However, the exact cause and treatment are not fully understood. Therefore, further research should focus on myokines whose expression is exclusively induced by anaerobic exercise. Searching for the cause of skeletal muscle loss and its biomarkers will provide clues to the prevention of geriatric diseases and development of new treatments. This review provides scientific evidence that can be used by health practitioners to develop and promote exercise programs or interventions that maintain the balance between aerobic and anaerobic exercises for the elderly. Skeletal muscle loss in the elderly is not just a personal problem but also a social problem. Considering the huge medical costs associated with the treatment of sarcopenia and osteoporotic fractures [278,279]—which impose a huge tax burden on all members of society—recreational therapists, researchers, policymakers, and clinicians are urged to work together to improve the health of the elderly. 4. Conclusions Myokines are secreted in response to skeletal muscle contractions during exercise and are promising anti-aging molecules due to their benefits in age-related diseases. Our review provides a conceptual basis for understanding different exercise-induced myokines and their therapeutic roles in helping the elderly remain healthy. We found that myokines are produced in response to regular exercise and play a key role in preventing or attenuating aging-related disease, such as dementia, obesity, diabetes, and cardiovascular and metabolic diseases. Although the 13 myokines reviewed are all stimulated by exercise, each has unique characteristics. In brief, apelin is an anti-aging factor and has positive effects on hypertension and ischemia-reperfusion injury when combined with exercise. BAIBA prevents metabolic diseases by acting as an osteocyte survival factor, protecting against mitochondrial breakdown, and attenuating bone and skeletal muscle loss. BMP-7 is an important factor in bone formation and skeletal muscle mass maintenance. Decorin, IGF-1, and SDF-1 have positive effects on tendon strength, bone and tissue development, and skeletal muscle regeneration, respectively. IL-15 facilitates fibroblast collagen synthesis and cell proliferation. IL-6 contributes to the maintenance of glucose homeostasis, obesity regulation, microglial function, and lactate production. Irisin might become a treatment for Alzheimer’s disease because of its positive influence on neuron functional impairment. The most interesting is myostatin. Unlike the other myokines, exercise reduces its secretion. It is beneficial in chronic heart failure, chronic kidney disease, and lipidomic abnormalities. Sestrin helps prevent the development of age-associated metabolic diseases and sarcopenia. SPARC, which is increased by aerobic exercise, has potential as a cancer treatment. VEGF-A, which is upregulated by both anaerobic and aerobic exercise, is involved in the growth and survival of skeletal muscle. Author Contributions J.H.K., K.M.M. and K.-W.M.; formal analysis, J.H.K. and K.M.M.; writing-original draft, J.H.K.; writing-review and editing, K.M.M. All authors have read and agreed to the published version of the manuscript. Funding This research received no external funding Conflicts of Interest The authors have no conflicts of interest to declare. ==== Refs References 1. Kalache A. Gatti A. Active ageing: A policy framework Adv. Gerontol. 2003 11 7 18 12820516 2. Mitchell W.K. Williams J. Atherton P. Larvin M. Lund J. Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review Front. Physiol. 2012 3 260 10.3389/fphys.2012.00260 22934016 3. Zierer J. Pallister T. Tsai P.C. Krumsiek J. Bell J.T. Lauc G. Spector T.D. Menni C. Kastenmuller G. Exploring the molecular basis of age-related disease comorbidities using a multi-omics graphical model Sci. Rep. 2016 6 37646 10.1038/srep37646 27886242 4. Department of Health, P.A., Health Improvement and Protection Start Active, Stay Active: A Report on Physical Activity for Health from the Four Home Countries’ Chief Medical Officers Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/830943/withdrawn_dh_128210.pdf (accessed on 9 September 2020) 5. de Sire R. Rizzatti G. Ingravalle F. Pizzoferrato M. Petito V. Lopetuso L. Graziani C. de Sire A. Mentella M.C. Mele M.C. Skeletal muscle-gut axis: Emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases Minerva Gastroenterol. Dietol. 2018 64 351 362 10.23736/S1121-421X.18.02511-4 30016852 6. Roubenoff R. Hughes V.A. Sarcopenia: Current concepts J. Gerontol. A Biol. Sci. Med. Sci. 2000 55 M716 M724 10.1093/gerona/55.12.M716 11129393 7. Gianoudis J. Bailey C.A. Daly R.M. Associations between sedentary behaviour and body composition, muscle function and sarcopenia in community-dwelling older adults Osteoporos Int. 2015 26 571 579 10.1007/s00198-014-2895-y 25245026 8. Critchley M. The neurology of old age Lancet 1931 217 1119 1127 10.1016/S0140-6736(00)90705-0 9. Arango-Lopera V.E. Arroyo P. Gutierrez-Robledo L.M. Perez-Zepeda M.U. Cesari M. Mortality as an adverse outcome of sarcopenia J. Nutr. Health Aging 2013 17 259 262 10.1007/s12603-012-0434-0 23459979 10. Brady A.O. Straight C.R. Evans E.M. Body composition, muscle capacity, and physical function in older adults: An integrated conceptual model J. Aging Phys. Act. 2014 22 441 452 10.1123/JAPA.2013-0009 23945551 11. Trombetti A. Reid K.F. Hars M. Herrmann F.R. Pasha E. Phillips E.M. Fielding R.A. Age-associated declines in muscle mass, strength, power, and physical performance: Impact on fear of falling and quality of life Osteoporos Int. 2016 27 463 471 10.1007/s00198-015-3236-5 26194491 12. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks Available online: https://apps.who.int/iris/handle/10665/44203 (accessed on 29 September 2020) 13. Frontera W.R. Ochala J. Skeletal muscle: A brief review of structure and function Calcif. Tissue Int. 2015 96 183 195 10.1007/s00223-014-9915-y 25294644 14. Broholm C. Mortensen O.H. Nielsen S. Akerstrom T. Zankari A. Dahl B. Pedersen B.K. Exercise induces expression of leukaemia inhibitory factor in human skeletal muscle J. Physiol. 2008 586 2195 2201 10.1113/jphysiol.2007.149781 18292129 15. Ouchi N. Oshima Y. Ohashi K. Higuchi A. Ikegami C. Izumiya Y. Walsh K. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism J. Biol. Chem. 2008 283 32802 32811 10.1074/jbc.M803440200 18718903 16. Pedersen B.K. Akerstrom T.C. Nielsen A.R. Fischer C.P. Role of myokines in exercise and metabolism J. Appl. Physiol. 2007 103 1093 1098 10.1152/japplphysiol.00080.2007 17347387 17. Pal M. Febbraio M.A. Whitham M. From cytokine to myokine: The emerging role of interleukin-6 in metabolic regulation Immunol. Cell Biol. 2014 92 331 339 10.1038/icb.2014.16 24751614 18. Bruunsgaard H. Galbo H. Halkjaer-Kristensen J. Johansen T.L. MacLean D.A. Pedersen B.K. Exercise-induced increase in serum interleukin-6 in humans is related to muscle damage J. Physiol. 1997 499 Pt 3 833 841 10.1113/jphysiol.1997.sp021972 9130176 19. Pedersen B.K. Febbraio M.A. Muscle as an endocrine organ: Focus on muscle-derived interleukin-6 Physiol. Rev. 2008 88 1379 1406 10.1152/physrev.90100.2007 18923185 20. Jonsdottir I.H. Schjerling P. Ostrowski K. Asp S. Richter E.A. Pedersen B.K. Muscle contractions induce interleukin-6 mRNA production in rat skeletal muscles J. Physiol. 2000 528 Pt 1 157 163 10.1111/j.1469-7793.2000.00157.x 11018114 21. Steensberg A. van Hall G. Osada T. Sacchetti M. Saltin B. Klarlund Pedersen B. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6 J. Physiol. 2000 529 Pt 1 237 242 10.1111/j.1469-7793.2000.00237.x 11080265 22. Nedachi T. Fujita H. Kanzaki M. Contractile C2C12 myotube model for studying exercise-inducible responses in skeletal muscle Am. J. Physiol. Endocrinol. Metab. 2008 295 E1191 E1204 10.1152/ajpendo.90280.2008 18780777 23. Farmawati A. Kitajima Y. Nedachi T. Sato M. Kanzaki M. Nagatomi R. Characterization of contraction-induced IL-6 up-regulation using contractile C2C12 myotubes Endocr. J. 2013 60 137 147 10.1507/endocrj.EJ12-0316 23037942 24. Whitham M. Chan M.H. Pal M. Matthews V.B. Prelovsek O. Lunke S. El-Osta A. Broenneke H. Alber J. Bruning J.C. Contraction-induced interleukin-6 gene transcription in skeletal muscle is regulated by c-Jun terminal kinase/activator protein-1 J. Biol. Chem. 2012 287 10771 10779 10.1074/jbc.M111.310581 22351769 25. Furuichi Y. Manabe Y. Takagi M. Aoki M. Fujii N.L. Evidence for acute contraction-induced myokine secretion by C2C12 myotubes PLoS ONE 2018 13 e0206146 10.1371/journal.pone.0206146 30356272 26. Pourteymour S. Eckardt K. Holen T. Langleite T. Lee S. Jensen J. Birkeland K.I. Drevon C.A. Hjorth M. Global mRNA sequencing of human skeletal muscle: Search for novel exercise-regulated myokines Mol. Metab. 2017 6 352 365 10.1016/j.molmet.2017.01.007 28377874 27. Leal L.G. Lopes M.A. Batista M.L. Jr. Physical exercise-induced myokines and muscle-adipose tissue crosstalk: A review of current knowledge and the implications for health and metabolic diseases Front. Physiol. 2018 9 1307 10.3389/fphys.2018.01307 30319436 28. Fiuza-Luces C. Santos-Lozano A. Joyner M. Carrera-Bastos P. Picazo O. Zugaza J.L. Izquierdo M. Ruilope L.M. Lucia A. Exercise benefits in cardiovascular disease: Beyond attenuation of traditional risk factors Nat. Rev. Cardiol. 2018 15 731 743 10.1038/s41569-018-0065-1 30115967 29. Tatemoto K. Hosoya M. Habata Y. Fujii R. Kakegawa T. Zou M.X. Kawamata Y. Fukusumi S. Hinuma S. Kitada C. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor Biochem. Biophys. Res. Commun. 1998 251 471 476 10.1006/bbrc.1998.9489 9792798 30. Lee D.K. Cheng R. Nguyen T. Fan T. Kariyawasam A.P. Liu Y. Osmond D.H. George S.R. O’Dowd B.F. Characterization of apelin, the ligand for the APJ receptor J. Neurochem. 2000 74 34 41 10.1046/j.1471-4159.2000.0740034.x 10617103 31. Habata Y. Fujii R. Hosoya M. Fukusumi S. Kawamata Y. Hinuma S. Kitada C. Nishizawa N. Murosaki S. Kurokawa T. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum Biochim. Biophys. Acta 1999 1452 25 35 10.1016/S0167-4889(99)00114-7 10525157 32. Tatemoto K. Takayama K. Zou M.X. Kumaki I. Zhang W. Kumano K. Fujimiya M. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism Regul. Pept. 2001 99 87 92 10.1016/S0167-0115(01)00236-1 11384769 33. Szokodi I. Tavi P. Foldes G. Voutilainen-Myllyla S. Ilves M. Tokola H. Pikkarainen S. Piuhola J. Rysa J. Toth M. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility Circ. Res. 2002 91 434 440 10.1161/01.RES.0000033522.37861.69 12215493 34. Zhang L. Takara K. Yamakawa D. Kidoya H. Takakura N. Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy Cancer Sci. 2016 107 36 44 10.1111/cas.12836 26475217 35. Zhang J. Liu Q. Fang Z. Hu X. Huang F. Tang L. Zhou S. Hypoxia induces the proliferation of endothelial progenitor cells via upregulation of Apelin/APLNR/MAPK signaling Mol. Med. Rep. 2016 13 1801 1806 10.3892/mmr.2015.4691 26676468 36. Boucher J. Masri B. Daviaud D. Gesta S. Guigne C. Mazzucotelli A. Castan-Laurell I. Tack I. Knibiehler B. Carpene C. Apelin, a newly identified adipokine up-regulated by insulin and obesity Endocrinology 2005 146 1764 1771 10.1210/en.2004-1427 15677759 37. Li L. Yang G. Li Q. Tang Y. Yang M. Yang H. Li K. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects Exp. Clin. Endocrinol. Diabetes 2006 114 544 548 10.1055/s-2006-948309 17177135 38. Masoumi J. Jafarzadeh A. Khorramdelazad H. Abbasloui M. Abdolalizadeh J. Jamali N. Role of Apelin/APJ axis in cancer development and progression Adv. Med. Sci. 2020 65 202 213 10.1016/j.advms.2020.02.002 32087570 39. Besse-Patin A. Montastier E. Vinel C. Castan-Laurell I. Louche K. Dray C. Daviaud D. Mir L. Marques M.A. Thalamas C. Effect of endurance training on skeletal muscle myokine expression in obese men: Identification of apelin as a novel myokine Int. J. Obes. 2014 38 707 713 10.1038/ijo.2013.158 40. Vinel C. Lukjanenko L. Batut A. Deleruyelle S. Pradere J.P. Le Gonidec S. Dortignac A. Geoffre N. Pereira O. Karaz S. The exerkine apelin reverses age-associated sarcopenia Nat. Med. 2018 24 1360 1371 10.1038/s41591-018-0131-6 30061698 41. Rai R. Ghosh A.K. Eren M. Mackie A.R. Levine D.C. Kim S.Y. Cedernaes J. Ramirez V. Procissi D. Smith L.H. Downregulation of the apelinergic axis accelerates aging, whereas its systemic restoration improves the mammalian healthspan Cell Rep. 2017 21 1471 1480 10.1016/j.celrep.2017.10.057 29117554 42. Zhang J. Ren C.X. Qi Y.F. Lou L.X. Chen L. Zhang L.K. Wang X. Tang C. Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats Life Sci. 2006 79 1153 1159 10.1016/j.lfs.2006.03.040 16674982 43. Kwak S.E. Cho S.C. Bae J.H. Lee J. Shin H.E. Zhang D.D. Lee Y.I. Song W. Effects of exercise-induced apelin on muscle function and cognitive function in aged mice Exp. Gerontol. 2019 127 110710 10.1016/j.exger.2019.110710 31473200 44. Nazari A. Chehelcheraghi F. Using Apelin and exercise to protect the cardiac cells: Synergic effect in ischemia reperfusion injuries treatment in rats Bratisl. Lek. Listy 2020 121 14 21 10.4149/BLL_2020_003 31950835 45. Crumpler H.R. Dent C.E. Harris H. Westall R.G. β-Aminoisobutyric acid (α-methyl-β-alanine); a new amino-acid obtained from human urine Nature 1951 167 307 308 10.1038/167307a0 14806475 46. Roberts L.D. Bostrom P. O’Sullivan J.F. Schinzel R.T. Lewis G.D. Dejam A. Lee Y.K. Palma M.J. Calhoun S. Georgiadi A. beta-Aminoisobutyric acid induces browning of white fat and hepatic beta-oxidation and is inversely correlated with cardiometabolic risk factors Cell Metab. 2014 19 96 108 10.1016/j.cmet.2013.12.003 24411942 47. Schnyder S. Handschin C. Skeletal muscle as an endocrine organ: PGC-1alpha, myokines and exercise Bone 2015 80 115 125 10.1016/j.bone.2015.02.008 26453501 48. Kammoun H.L. Febbraio M.A. Come on BAIBA light my fire Cell Metab. 2014 19 1 2 10.1016/j.cmet.2013.12.007 24411934 49. Shi C.X. Zhao M.X. Shu X.D. Xiong X.Q. Wang J.J. Gao X.Y. Chen Q. Li Y.H. Kang Y.M. Zhu G.Q. β-aminoisobutyric acid attenuates hepatic endoplasmic reticulum stress and glucose/lipid metabolic disturbance in mice with type 2 diabetes Sci. Rep. 2016 6 21924 10.1038/srep21924 26907958 50. Tanianskii D.A. Jarzebska N. Birkenfeld A.L. O’Sullivan J.F. Rodionov R.N. Beta-aminoisobutyric acid as a novel regulator of carbohydrate and lipid metabolism Nutrients 2019 11 524 10.3390/nu11030524 51. Fazelzadeh P. Hangelbroek R.W. Tieland M. de Groot L.C. Verdijk L.B. van Loon L.J. Smilde A.K. Alves R.D. Vervoort J. Muller M. The muscle metabolome differs between healthy and frail older adults J. Proteome Res. 2016 15 499 509 10.1021/acs.jproteome.5b00840 26732810 52. Ginter E. Simko V. Recent data on obesity research: Beta-aminoisobutyric acid Bratisl. Lek. Listy 2014 115 492 493 10.4149/BLL_2014_095 25246285 53. Hangelbroek R.W. Fazelzadeh P. Tieland M. Boekschoten M.V. Hooiveld G.J. van Duynhoven J.P. Timmons J.A. Verdijk L.B. de Groot L.C. van Loon L.J. Expression of protocadherin gamma in skeletal muscle tissue is associated with age and muscle weakness J. Cachexia Sarcopenia Muscle 2016 7 604 614 10.1002/jcsm.12099 27239416 54. Kitase Y. Vallejo J.A. Gutheil W. Vemula H. Jahn K. Yi J. Zhou J. Brotto M. Bonewald L.F. β-Aminoisobutyric acid, l-BAIBA, is a muscle-derived osteocyte survival factor Cell Rep. 2018 22 1531 1544 10.1016/j.celrep.2018.01.041 29425508 55. Bonewald L. Use it or lose it to age: A review of bone and muscle communication Bone 2019 120 212 218 10.1016/j.bone.2018.11.002 30408611 56. Wang Z. Bian L. Mo C. Shen H. Zhao L.J. Su K.J. Kukula M. Lee J.T. Armstrong D.W. Recker R. Quantification of aminobutyric acids and their clinical applications as biomarkers for osteoporosis Commun. Biol. 2020 3 39 10.1038/s42003-020-0766-y 31969651 57. Hatazawa Y. Senoo N. Tadaishi M. Ogawa Y. Ezaki O. Kamei Y. Miura S. Metabolomic analysis of the skeletal muscle of mice overexpressing PGC-1alpha PLoS ONE 2015 10 e0129084 10.1371/journal.pone.0129084 26114427 58. Stautemas J. Van Kuilenburg A.B.P. Stroomer L. Vaz F. Blancquaert L. Lefevere F.B.D. Everaert I. Derave W. Acute aerobic exercise leads to increased plasma levels of R- and S-β-aminoisobutyric acid in humans Front. Physiol. 2019 10 1240 10.3389/fphys.2019.01240 31611815 59. Kamei Y. Hatazawa Y. Uchitomi R. Yoshimura R. Miura S. Regulation of skeletal muscle function by amino acids Nutrients 2020 12 261 10.3390/nu12010261 60. Short K.R. Chadwick J.Q. Teague A.M. Tullier M.A. Wolbert L. Coleman C. Copeland K.C. Effect of obesity and exercise training on plasma amino acids and amino metabolites in American Indian adolescents J. Clin. Endocrinol. Metab. 2019 104 3249 3261 10.1210/jc.2018-02698 31216576 61. Molfino A. Amabile M.I. Ammann T. Farcomeni A. Lionetto L. Simmaco M. Lai S. Laviano A. Rossi Fanelli F. Chiappini M.G. The metabolite beta-aminoisobutyric acid and physical inactivity among hemodialysis patients Nutrition 2017 34 101 107 10.1016/j.nut.2016.07.012 28063504 62. Molfino A. Amabile M.I. Ammann T. Lai S. Grosso A. Lionetto L. Spagnoli A. Simmaco M. Monti M. Laviano A. Longitudinal physical activity change during hemodialysis and its association with body composition and plasma BAIBA levels Front. Physiol. 2019 10 805 10.3389/fphys.2019.00805 31293456 63. Urist M.R. Bone: Formation by autoinduction Science 1965 150 893 899 10.1126/science.150.3698.893 5319761 64. Mitu G. Hirschberg R. Bone morphogenetic protein-7 (BMP7) in chronic kidney disease Front. Biosci. 2008 13 4726 4739 10.2741/3035 18508541 65. Pesonen E. Merritt A.T. Heldt G. Sahn D.J. Elias W. Tikkanen I. Fyhrquist F. Andersson S. Correlation of patent ductus arteriosus shunting with plasma atrial natriuretic factor concentration in preterm infants with respiratory distress syndrome Pediatr. Res. 1990 27 137 139 10.1203/00006450-199002000-00010 2138278 66. Ozkaynak E. Rueger D.C. Drier E.A. Corbett C. Ridge R.J. Sampath T.K. Oppermann H. OP-1 cDNA encodes an osteogenic protein in the TGF-beta family EMBO J. 1990 9 2085 2093 10.1002/j.1460-2075.1990.tb07376.x 2357959 67. Hahn G.V. Cohen R.B. Wozney J.M. Levitz C.L. Shore E.M. Zasloff M.A. Kaplan F.S. A bone morphogenetic protein subfamily: Chromosomal localization of human genes for BMP5, BMP6, and BMP7 Genomics 1992 14 759 762 10.1016/S0888-7543(05)80181-8 1427904 68. Ripamonti U. Reddi A.H. Tissue engineering, morphogenesis, and regeneration of the periodontal tissues by bone morphogenetic proteins Crit. Rev. Oral Biol. Med. 1997 8 154 163 10.1177/10454411970080020401 9167090 69. Chen D. Zhao M. Mundy G.R. Bone morphogenetic proteins Growth Fact. 2004 22 233 241 10.1080/08977190412331279890 70. Schulz T.J. Huang T.L. Tran T.T. Zhang H. Townsend K.L. Shadrach J.L. Cerletti M. McDougall L.E. Giorgadze N. Tchkonia T. Identification of inducible brown adipocyte progenitors residing in skeletal muscle and white fat Proc. Natl. Acad. Sci. USA 2011 108 143 148 10.1073/pnas.1010929108 21173238 71. Saini S. Duraisamy A.J. Bayen S. Vats P. Singh S.B. Role of BMP7 in appetite regulation, adipogenesis, and energy expenditure Endocrine 2015 48 405 409 10.1007/s12020-014-0406-8 25178649 72. Chubinskaya S. Kumar B. Merrihew C. Heretis K. Rueger D.C. Kuettner K.E. Age-related changes in cartilage endogenous osteogenic protein-1 (OP-1) Biochim. Biophys. Acta 2002 1588 126 134 10.1016/S0925-4439(02)00158-8 12385776 73. Kim J.S. Lee Y.H. Yi H.K. Gradual downhill running improves age-related skeletal muscle and bone weakness: Implication of autophagy and bone morphogenetic proteins Exp. Physiol. 2016 101 1528 1540 10.1113/EP085852 27641238 74. Merrihew C. Kumar B. Heretis K. Rueger D.C. Kuettner K.E. Chubinskaya S. Alterations in endogenous osteogenic protein-1 with degeneration of human articular cartilage J. Orthop. Res. 2003 21 899 907 10.1016/S0736-0266(03)00055-X 12919879 75. Loeser R.F. Im H.J. Richardson B. Lu Q. Chubinskaya S. Methylation of the OP-1 promoter: Potential role in the age-related decline in OP-1 expression in cartilage Osteoarthr. Cartil. 2009 17 513 517 10.1016/j.joca.2008.08.003 18829350 76. Yeh L.C. Tsai A.D. Lee J.C. Osteogenic protein-1 (OP-1, BMP-7) induces osteoblastic cell differentiation of the pluripotent mesenchymal cell line C2C12 J. Cell. Biochem. 2002 87 292 304 10.1002/jcb.10315 12397611 77. Winbanks C.E. Chen J.L. Qian H. Liu Y. Bernardo B.C. Beyer C. Watt K.I. Thomson R.E. Connor T. Turner B.J. The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass J. Cell Biol. 2013 203 345 357 10.1083/jcb.201211134 24145169 78. Nam J. Perera P. Rath B. Agarwal S. Dynamic regulation of bone morphogenetic proteins in engineered osteochondral constructs by biomechanical stimulation Tissue Eng. Part A 2013 19 783 792 10.1089/ten.tea.2012.0103 23198877 79. Rocha-Rodrigues S. Rodriguez A. Gouveia A.M. Goncalves I.O. Becerril S. Ramirez B. Beleza J. Fruhbeck G. Ascensao A. Magalhaes J. Effects of physical exercise on myokines expression and brown adipose-like phenotype modulation in rats fed a high-fat diet Life Sci. 2016 165 100 108 10.1016/j.lfs.2016.09.023 27693382 80. Vetter U. Vogel W. Just W. Young M.F. Fisher L.W. Human decorin gene: Intron-exon junctions and chromosomal localization Genomics 1993 15 161 168 10.1006/geno.1993.1023 8432527 81. Droguett R. Cabello-Verrugio C. Riquelme C. Brandan E. Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation Matrix Biol. 2006 25 332 341 10.1016/j.matbio.2006.04.004 16766169 82. Kanzleiter T. Rath M. Gorgens S.W. Jensen J. Tangen D.S. Kolnes A.J. Kolnes K.J. Lee S. Eckel J. Schurmann A. The myokine decorin is regulated by contraction and involved in muscle hypertrophy Biochem. Biophys. Res. Commun. 2014 450 1089 1094 10.1016/j.bbrc.2014.06.123 24996176 83. Vuillermoz B. Wegrowski Y. Contet-Audonneau J.L. Danoux L. Pauly G. Maquart F.X. Influence of aging on glycosaminoglycans and small leucine-rich proteoglycans production by skin fibroblasts Mol. Cell. Biochem. 2005 277 63 72 10.1007/s11010-005-5073-x 16132716 84. Batbayal T. Ishii Y. Nomura Y. Watanabe M. Yasuko T. Nakamura S. Change in decorin during aging of rat placenta Connect. Tissue Res. 2006 47 235 241 10.1080/03008200600883138 16987756 85. Li Y. Liu Y. Xia W. Lei D. Voorhees J.J. Fisher G.J. Age-dependent alterations of decorin glycosaminoglycans in human skin Sci. Rep. 2013 3 2422 10.1038/srep02422 23939413 86. Dunkman A.A. Buckley M.R. Mienaltowski M.J. Adams S.M. Thomas S.J. Satchell L. Kumar A. Pathmanathan L. Beason D.P. Iozzo R.V. Decorin expression is important for age-related changes in tendon structure and mechanical properties Matrix Biol. 2013 32 3 13 10.1016/j.matbio.2012.11.005 23178232 87. Dunkman A.A. Buckley M.R. Mienaltowski M.J. Adams S.M. Thomas S.J. Kumar A. Beason D.P. Iozzo R.V. Birk D.E. Soslowsky L.J. The injury response of aged tendons in the absence of biglycan and decorin Matrix Biol. 2014 35 232 238 10.1016/j.matbio.2013.10.008 24157578 88. Visser N.A. de Koning M.H. Lammi M.J. Hakkinen T. Tammi M. van Kampen G.P. Increase of decorin content in articular cartilage following running Connect. Tissue Res. 1998 37 295 302 10.3109/03008209809002446 9862228 89. Heinemeier K.M. Bjerrum S.S. Schjerling P. Kjaer M. Expression of extracellular matrix components and related growth factors in human tendon and muscle after acute exercise Scand. J. Med. Sci. Sports 2013 23 e150 e161 10.1111/j.1600-0838.2011.01414.x 22107086 90. Xu S.Y. Liu S.Y. Xu L. Deng S.Y. He Y.B. Li S.F. Ni G.X. Response of decorin to different intensity treadmill running Mol. Med. Rep. 2018 17 7911 7917 10.3892/mmr.2018.8802 29620182 91. Salmon W.D. Jr. Daughaday W.H. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro J. Lab. Clin. Med. 1957 49 825 836 13429201 92. Rinderknecht E. Humbel R.E. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin J. Biol. Chem. 1978 253 2769 2776 632300 93. Jansen M. van Schaik F.M. Ricker A.T. Bullock B. Woods D.E. Gabbay K.H. Nussbaum A.L. Sussenbach J.S. Van den Brande J.L. Sequence of cDNA encoding human insulin-like growth factor I precursor Nature 1983 306 609 611 10.1038/306609a0 6358902 94. Hoppener J.W. de Pagter-Holthuizen P. Geurts van Kessel A.H. Jansen M. Kittur S.D. Antonarakis S.E. Lips C.J. Sussenbach J.S. The human gene encoding insulin-like growth factor I is located on chromosome 12 Hum. Genet. 1985 69 157 160 10.1007/BF00293288 2982726 95. Neirijnck Y. Papaioannou M.D. Nef S. The insulin/IGF system in mammalian sexual development and reproduction Int. J. Mol. Sci. 2019 20 4440 10.3390/ijms20184440 31505893 96. Pedersen B.K. Febbraio M.A. Muscles, exercise and obesity: Skeletal muscle as a secretory organ Nat. Rev. Endocrinol. 2012 8 457 465 10.1038/nrendo.2012.49 22473333 97. Bando H. Zhang C. Takada Y. Yamasaki R. Saito S. Impaired secretion of growth hormone-releasing hormone, growth hormone and IGF-I in elderly men Acta Endocrinol. 1991 124 31 36 10.1530/acta.0.1240031 2000699 98. Yamamoto H. Sohmiya M. Oka N. Kato Y. Effects of aging and sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults Acta Endocrinol. 1991 124 497 500 10.1530/acta.0.1240497 99. Ceda G.P. Dall’Aglio E. Magnacavallo A. Vargas N. Fontana V. Maggio M. Valenti G. Lee P.D. Hintz R.L. Hoffman A.R. The insulin-like growth factor axis and plasma lipid levels in the elderly J. Clin. Endocrinol. Metab. 1998 83 499 502 10.1210/jc.83.2.499 9467564 100. Krishnaraj R. Zaks A. Unterman T. Relationship between plasma IGF-I levels, in vitro correlates of immunity, and human senescence Clin. Immunol. Immunopathol. 1998 88 264 270 10.1006/clin.1998.4578 9743613 101. Kucera R. Topolcan O. Pecen L. Kinkorova J. Svobodova S. Windrichova J. Fuchsova R. Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic Clin. Chim. Acta 2015 444 271 277 10.1016/j.cca.2015.02.036 25744488 102. Sell C. Ptasznik A. Chang C.D. Swantek J. Cristofalo V.J. Baserga R. IGF-1 receptor levels and the proliferation of young and senescent human fibroblasts Biochem. Biophys. Res. Commun. 1993 194 259 265 10.1006/bbrc.1993.1813 7687431 103. Kveiborg M. Flyvbjerg A. Rattan S.I. Kassem M. Changes in the insulin-like growth factor-system may contribute to in vitro age-related impaired osteoblast functions Exp. Gerontol. 2000 35 1061 1074 10.1016/S0531-5565(00)00125-X 11121690 104. Gong Z. Kennedy O. Sun H. Wu Y. Williams G.A. Klein L. Cardoso L. Matheny R.W. Jr. Hubbard G.B. Ikeno Y. Reductions in serum IGF-1 during aging impair health span Aging Cell 2014 13 408 418 10.1111/acel.12188 24341939 105. Pharaoh G. Owen D. Yeganeh A. Premkumar P. Farley J. Bhaskaran S. Ashpole N. Kinter M. Van Remmen H. Logan S. Disparate central and peripheral effects of circulating IGF-1 deficiency on tissue mitochondrial function Mol. Neurobiol. 2020 57 1317 1331 10.1007/s12035-019-01821-4 31732912 106. Tay L. Ding Y.Y. Leung B.P. Ismail N.H. Yeo A. Yew S. Tay K.S. Tan C.H. Chong M.S. Sex-specific differences in risk factors for sarcopenia amongst community-dwelling older adults Age 2015 37 121 10.1007/s11357-015-9860-3 26607157 107. Chew J. Tay L. Lim J.P. Leung B.P. Yeo A. Yew S. Ding Y.Y. Lim W.S. Serum myostatin and IGF-1 as gender-specific biomarkers of frailty and low muscle mass in community-dwelling older adults J. Nutr. Health Aging 2019 23 979 986 10.1007/s12603-019-1255-1 31781728 108. Deuschle M. Blum W.F. Frystyk J. Orskov H. Schweiger U. Weber B. Korner A. Gotthardt U. Schmider J. Standhardt H. Endurance training and its effect upon the activity of the GH-IGFs system in the elderly Int. J. Sports Med. 1998 19 250 254 10.1055/s-2007-971913 9657364 109. Singh M.A. Ding W. Manfredi T.J. Solares G.S. O’Neill E.F. Clements K.M. Ryan N.D. Kehayias J.J. Fielding R.A. Evans W.J. Insulin-like growth factor I in skeletal muscle after weight-lifting exercise in frail elders Am. J. Physiol. 1999 277 E135 E143 10.1152/ajpendo.1999.277.1.E135 10409137 110. Liu M. Stevens-Lapsley J.E. Jayaraman A. Ye F. Conover C. Walter G.A. Bose P. Thompson F.J. Borst S.E. Vandenborne K. Impact of treadmill locomotor training on skeletal muscle IGF1 and myogenic regulatory factors in spinal cord injured rats Eur. J. Appl. Physiol. 2010 109 709 720 10.1007/s00421-010-1392-z 20213470 111. Dieli-Conwright C.M. Kiwata J.L. Tuzon C.T. Spektor T.M. Sattler F.R. Rice J.C. Schroeder E.T. Acute response of PGC-1alpha and IGF-1 isoforms to maximal eccentric exercise in skeletal muscle of postmenopausal women J. Strength Cond. Res. 2016 30 1161 1170 10.1519/JSC.0000000000001171 26340467 112. Burton J.D. Bamford R.N. Peters C. Grant A.J. Kurys G. Goldman C.K. Brennan J. Roessler E. Waldmann T.A. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells Proc. Natl. Acad. Sci. USA 1994 91 4935 4939 10.1073/pnas.91.11.4935 8197160 113. Grabstein K.H. Eisenman J. Shanebeck K. Rauch C. Srinivasan S. Fung V. Beers C. Richardson J. Schoenborn M.A. Ahdieh M. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor Science 1994 264 965 968 10.1126/science.8178155 8178155 114. Steel J.C. Waldmann T.A. Morris J.C. Interleukin-15 biology and its therapeutic implications in cancer Trends Pharmacol. Sci. 2012 33 35 41 10.1016/j.tips.2011.09.004 22032984 115. Quinn L.S. Anderson B.G. Interleukin-15, IL-15 receptor-alpha, and obesity: Concordance of laboratory animal and human genetic studies J. Obes. 2011 2011 456347 10.1155/2011/456347 21603270 116. Klebanoff C.A. Finkelstein S.E. Surman D.R. Lichtman M.K. Gattinoni L. Theoret M.R. Grewal N. Spiess P.J. Antony P.A. Palmer D.C. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells Proc. Natl. Acad. Sci. USA 2004 101 1969 1974 10.1073/pnas.0307298101 14762166 117. Malamut G. El Machhour R. Montcuquet N. Martin-Lanneree S. Dusanter-Fourt I. Verkarre V. Mention J.J. Rahmi G. Kiyono H. Butz E.A. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis J. Clin. Investig. 2010 120 2131 2143 10.1172/JCI41344 20440074 118. Wu J. IL-15 agonists: The cancer cure cytokine J. Mol. Genet. Med. 2013 7 85 10.4172/1747-0862.1000085 24587813 119. Brandt C. Pedersen B.K. The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases J. Biomed. Biotechnol. 2010 2010 520258 10.1155/2010/520258 20224659 120. Marzetti E. Carter C.S. Wohlgemuth S.E. Lees H.A. Giovannini S. Anderson B. Quinn L.S. Leeuwenburgh C. Changes in IL-15 expression and death-receptor apoptotic signaling in rat gastrocnemius muscle with aging and life-long calorie restriction Mech. Ageing Dev. 2009 130 272 280 10.1016/j.mad.2008.12.008 19396981 121. Quinn L.S. Anderson B.G. Strait-Bodey L. Wolden-Hanson T. Serum and muscle interleukin-15 levels decrease in aging mice: Correlation with declines in soluble interleukin-15 receptor alpha expression Exp. Gerontol. 2010 45 106 112 10.1016/j.exger.2009.10.012 19854259 122. Crane J.D. MacNeil L.G. Lally J.S. Ford R.J. Bujak A.L. Brar I.K. Kemp B.E. Raha S. Steinberg G.R. Tarnopolsky M.A. Exercise-stimulated interleukin-15 is controlled by AMPK and regulates skin metabolism and aging Aging Cell 2015 14 625 634 10.1111/acel.12341 25902870 123. Yalcin A. Silay K. Balik A.R. Avcioglu G. Aydin A.S. The relationship between plasma interleukin-15 levels and sarcopenia in outpatient older people Aging Clin. Exp. Res. 2018 30 783 790 10.1007/s40520-017-0848-y 29071664 124. Nelke C. Dziewas R. Minnerup J. Meuth S.G. Ruck T. Skeletal muscle as potential central link between sarcopenia and immune senescence EBioMedicine 2019 49 381 388 10.1016/j.ebiom.2019.10.034 31662290 125. Cui G. Hara T. Simmons S. Wagatsuma K. Abe A. Miyachi H. Kitano S. Ishii M. Tani-ichi S. Ikuta K. Characterization of the IL-15 niche in primary and secondary lymphoid organs in vivo Proc. Natl. Acad. Sci. USA 2014 111 1915 1920 10.1073/pnas.1318281111 24449915 126. Riechman S.E. Balasekaran G. Roth S.M. Ferrell R.E. Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses J. Appl. Physiol. 2004 97 2214 2219 10.1152/japplphysiol.00491.2004 15531573 127. Perez-Lopez A. McKendry J. Martin-Rincon M. Morales-Alamo D. Perez-Kohler B. Valades D. Bujan J. Calbet J.A.L. Breen L. Skeletal muscle IL-15/IL-15Ralpha and myofibrillar protein synthesis after resistance exercise Scand. J. Med. Sci. Sports 2018 28 116 125 10.1111/sms.12901 28449327 128. Kim H.J. Park J.Y. Oh S.L. Kim Y.A. So B. Seong J.K. Song W. Effect of treadmill exercise on interleukin-15 expression and glucose tolerance in zucker diabetic fatty rats Diabetes Metab. J. 2013 37 358 364 10.4093/dmj.2013.37.5.358 24199165 129. Rinnov A. Yfanti C. Nielsen S. Akerstrom T.C. Peijs L. Zankari A. Fischer C.P. Pedersen B.K. Endurance training enhances skeletal muscle interleukin-15 in human male subjects Endocrine 2014 45 271 278 10.1007/s12020-013-9969-z 23649460 130. Hingorjo M.R. Zehra S. Saleem S. Qureshi M.A. Serum Interleukin-15 and its relationship with adiposity Indices before and after short-term endurance exercise Pak. J. Med. Sci. 2018 34 1125 1131 10.12669/pjms.345.15516 30344562 131. Yargic M.P. Torgutalp S. Akin S. Babayeva N. Torgutalp M. Demirel H.A. Acute long-distance trail running increases serum IL-6, IL-15, and Hsp72 levels Appl. Physiol. Nutr. Metab. 2019 44 627 631 10.1139/apnm-2018-0520 30365907 132. Brown J.A. Sherrod S.D. Goodwin C.R. Brewer B. Yang L. Garbett K.A. Li D. McLean J.A. Wikswo J.P. Mirnics K. Metabolic consequences of interleukin-6 challenge in developing neurons and astroglia J. Neuroinflamm. 2014 11 183 10.1186/s12974-014-0183-6 25374324 133. Kouda K. Furusawa K. Sugiyama H. Sumiya T. Ito T. Tajima F. Shimizu K. Does 20-min arm crank ergometer exercise increase plasma interleukin-6 in individuals with cervical spinal cord injury? Eur. J. Appl. Physiol. 2012 112 597 604 10.1007/s00421-011-2004-2 21617884 134. Zilberstein A. Ruggieri R. Korn J.H. Revel M. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines EMBO J. 1986 5 2529 2537 10.1002/j.1460-2075.1986.tb04531.x 3023045 135. Hirano T. Yasukawa K. Harada H. Taga T. Watanabe Y. Matsuda T. Kashiwamura S. Nakajima K. Koyama K. Iwamatsu A. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin Nature 1986 324 73 76 10.1038/324073a0 3491322 136. Sutherland G.R. Baker E. Callen D.F. Hyland V.J. Wong G. Clark S. Jones S.S. Eglinton L.K. Shannon M.F. Lopez A.F. Interleukin 4 is at 5q31 and interleukin 6 is at 7p15 Hum. Genet. 1988 79 335 337 10.1007/BF00282171 3261707 137. Yamasaki K. Taga T. Hirata Y. Yawata H. Kawanishi Y. Seed B. Taniguchi T. Hirano T. Kishimoto T. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor Science 1988 241 825 828 10.1126/science.3136546 3136546 138. Hibi M. Murakami M. Saito M. Hirano T. Taga T. Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130 Cell 1990 63 1149 1157 10.1016/0092-8674(90)90411-7 2261637 139. Wei J. Xu H. Davies J.L. Hemmings G.P. Increase of plasma IL-6 concentration with age in healthy subjects Life Sci. 1992 51 1953 1956 10.1016/0024-3205(92)90112-3 1453878 140. Ershler W.B. Sun W.H. Binkley N. Gravenstein S. Volk M.J. Kamoske G. Klopp R.G. Roecker E.B. Daynes R.A. Weindruch R. Interleukin-6 and aging: Blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction Lymphokine Cytokine Res. 1993 12 225 230 8218595 141. Hager K. Machein U. Krieger S. Platt D. Seefried G. Bauer J. Interleukin-6 and selected plasma proteins in healthy persons of different ages Neurobiol. Aging 1994 15 771 772 10.1016/0197-4580(94)90066-3 7534383 142. Kania D.M. Binkley N. Checovich M. Havighurst T. Schilling M. Ershler W.B. Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density J. Am. Geriatr. Soc. 1995 43 236 239 10.1111/j.1532-5415.1995.tb07328.x 7884109 143. Harris T.B. Ferrucci L. Tracy R.P. Corti M.C. Wacholder S. Ettinger W.H. Jr. Heimovitz H. Cohen H.J. Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly Am. J. Med. 1999 106 506 512 10.1016/S0002-9343(99)00066-2 10335721 144. Forcina L. Miano C. Scicchitano B.M. Rizzuto E. Berardinelli M.G. De Benedetti F. Pelosi L. Musaro A. Increased circulating levels of interleukin-6 affect the redox balance in skeletal muscle Oxid. Med. Cell. Longev. 2019 2019 3018584 10.1155/2019/3018584 31827671 145. Serrano A.L. Baeza-Raja B. Perdiguero E. Jardi M. Munoz-Canoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy Cell Metab. 2008 7 33 44 10.1016/j.cmet.2007.11.011 18177723 146. Abid H. Hart C. Lanza I. 3540 effects of local interleukin-6 on mitochondrial physiology in skeletal muscle J. Clin. Transl. Sci. 2019 3 10 10.1017/cts.2019.27 147. Sprenger H. Jacobs C. Nain M. Gressner A.M. Prinz H. Wesemann W. Gemsa D. Enhanced release of cytokines, interleukin-2 receptors, and neopterin after long-distance running Clin. Immunol. Immunopathol. 1992 63 188 195 10.1016/0090-1229(92)90012-D 1611721 148. Covington J.D. Tam C.S. Bajpeyi S. Galgani J.E. Noland R.C. Smith S.R. Redman L.M. Ravussin E. Myokine expression in muscle and myotubes in response to exercise stimulation Med. Sci. Sports Exerc. 2016 48 384 390 10.1249/MSS.0000000000000787 26460627 149. Briken S. Rosenkranz S.C. Keminer O. Patra S. Ketels G. Heesen C. Hellweg R. Pless O. Schulz K.H. Gold S.M. Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis J. Neuroimmunol. 2016 299 53 58 10.1016/j.jneuroim.2016.08.007 27725121 150. Cornish S.M. Chase J.E. Bugera E.M. Giesbrecht G.G. Systemic IL-6 and myoglobin response to three different resistance exercise intensities in older men J. Aging Phys. Act. 2018 26 451 456 10.1123/japa.2017-0167 29091530 151. Bugera E.M. Duhamel T.A. Peeler J.D. Cornish S.M. The systemic myokine response of decorin, interleukin-6 (IL-6) and interleukin-15 (IL-15) to an acute bout of blood flow restricted exercise Eur. J. Appl. Physiol. 2018 118 2679 2686 10.1007/s00421-018-3995-8 30244288 152. Eaton M. Granata C. Barry J. Safdar A. Bishop D. Little J.P. Impact of a single bout of high-intensity interval exercise and short-term interval training on interleukin-6, FNDC5, and METRNL mRNA expression in human skeletal muscle J. Sport Health Sci. 2018 7 191 196 10.1016/j.jshs.2017.01.003 30356443 153. Paulson T.A. Goosey-Tolfrey V.L. Lenton J.P. Leicht C.A. Bishop N.C. Spinal cord injury level and the circulating cytokine response to strenuous exercise Med. Sci. Sports Exerc. 2013 45 1649 1655 10.1249/MSS.0b013e31828f9bbb 23475168 154. Ogawa T. Nakamura T. Banno M. Sasaki Y. Umemoto Y. Kouda K. Kawasaki T. Tajima F. Elevation of interleukin-6 and attenuation of tumor necrosis factor-alpha during wheelchair half marathon in athletes with cervical spinal cord injuries Spinal Cord 2014 52 601 605 10.1038/sc.2014.88 24891006 155. Bobbo V.C.D. Jara C.P. Mendes N.F. Morari J. Velloso L.A. Araujo E.P. Interleukin-6 expression by hypothalamic microglia in multiple inflammatory contexts: A systematic review Biomed. Res. Int. 2019 2019 1365210 10.1155/2019/1365210 31534953 156. Hojman P. Brolin C. Norgaard-Christensen N. Dethlefsen C. Lauenborg B. Olsen C.K. Abom M.M. Krag T. Gehl J. Pedersen B.K. IL-6 release from muscles during exercise is stimulated by lactate-dependent protease activity Am. J. Physiol. Endocrinol. Metab. 2019 316 E940 E947 10.1152/ajpendo.00414.2018 30779630 157. Garneau L. Parsons S.A. Smith S.R. Mulvihill E.E. Sparks L.M. Aguer C. Plasma myokine concentrations after acute exercise in non-obese and obese sedentary women Front. Physiol. 2020 11 18 10.3389/fphys.2020.00018 32132925 158. Pedersen B.K. Fischer C.P. Beneficial health effects of exercise--the role of IL-6 as a myokine Trends Pharmacol. Sci. 2007 28 152 156 10.1016/j.tips.2007.02.002 17331593 159. Ellingsgaard H. Hojman P. Pedersen B.K. Exercise and health—Emerging roles of IL-6 Curr. Opin. Physiol. 2019 10 49 54 10.1016/j.cophys.2019.03.009 160. Teufel A. Malik N. Mukhopadhyay M. Westphal H. Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes Gene 2002 297 79 83 10.1016/S0378-1119(02)00828-4 12384288 161. Staiger H. Bohm A. Scheler M. Berti L. Machann J. Schick F. Machicao F. Fritsche A. Stefan N. Weigert C. Common genetic variation in the human FNDC5 locus, encoding the novel muscle-derived ’browning’ factor irisin, determines insulin sensitivity PLoS ONE 2013 8 e61903 10.1371/journal.pone.0061903 23637927 162. Novelle M.G. Contreras C. Romero-Pico A. Lopez M. Dieguez C. Irisin, two years later Int. J. Endocrinol. 2013 2013 746281 10.1155/2013/746281 24298283 163. Sanchis-Gomar F. Perez-Quilis C. The p38-PGC-1alpha-irisin-betatrophin axis: Exploring new pathways in insulin resistance Adipocyte 2014 3 67 68 10.4161/adip.27370 24575373 164. Huh J.Y. Mougios V. Kabasakalis A. Fatouros I. Siopi A. Douroudos I.I. Filippaios A. Panagiotou G. Park K.H. Mantzoros C.S. Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation J. Clin. Endocrinol. Metab. 2014 99 E2154 E2161 10.1210/jc.2014-1437 25119310 165. Chang J.S. Kim T.H. Nguyen T.T. Park K.S. Kim N. Kong I.D. Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study Geriatr. Gerontol. Int. 2017 17 2266 2273 10.1111/ggi.13030 28394089 166. Bi J. Yang L. Wang T. Zhang J. Li T. Ren Y. Wang M. Chen X. Lv Y. Wu R. Irisin improves autophagy of aged hepatocytes via increasing telomerase activity in liver injury Oxid. Med. Cell. Longev. 2020 2020 6946037 10.1155/2020/6946037 31976032 167. Ruan Q. Huang Y. Yang L. Ruan J. Gu W. Zhang X. Zhang Y. Zhang W. Yu Z. The effects of both age and sex on irisin levels in paired plasma and cerebrospinal fluid in healthy humans Peptides 2019 113 41 51 10.1016/j.peptides.2019.01.004 30716355 168. Rana K.S. Arif M. Hill E.J. Aldred S. Nagel D.A. Nevill A. Randeva H.S. Bailey C.J. Bellary S. Brown J.E. Plasma irisin levels predict telomere length in healthy adults Age 2014 36 995 1001 10.1007/s11357-014-9620-9 24469890 169. Huh J.Y. Panagiotou G. Mougios V. Brinkoetter M. Vamvini M.T. Schneider B.E. Mantzoros C.S. FNDC5 and irisin in humans: I. predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise Metabolism 2012 61 1725 1738 10.1016/j.metabol.2012.09.002 23018146 170. Lecker S.H. Zavin A. Cao P. Arena R. Allsup K. Daniels K.M. Joseph J. Schulze P.C. Forman D.E. Expression of the irisin precursor FNDC5 in skeletal muscle correlates with aerobic exercise performance in patients with heart failure Circ. Heart Fail. 2012 5 812 818 10.1161/CIRCHEARTFAILURE.112.969543 23001918 171. Brenmoehl J. Albrecht E. Komolka K. Schering L. Langhammer M. Hoeflich A. Maak S. Irisin is elevated in skeletal muscle and serum of mice immediately after acute exercise Int. J. Biol. Sci. 2014 10 338 349 10.7150/ijbs.7972 24644429 172. Kurdiova T. Balaz M. Vician M. Maderova D. Vlcek M. Valkovic L. Srbecky M. Imrich R. Kyselovicova O. Belan V. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: In vivo and in vitro studies J. Physiol. 2014 592 1091 1107 10.1113/jphysiol.2013.264655 24297848 173. Tsuchiya Y. Mizuno S. Goto K. Irisin response to downhill running exercise in humans J. Exerc. Nutr. Biochem. 2018 22 12 17 10.20463/jenb.2018.0011 30149421 174. Pang M. Yang J. Rao J. Wang H. Zhang J. Wang S. Chen X. Dong X. Time-dependent changes in increased levels of plasma irisin and muscle PGC-1alpha and FNDC5 after exercise in mice Tohoku J. Exp. Med. 2018 244 93 103 10.1620/tjem.244.93 29415899 175. Kang Y.S. Kim J.C. Kim J.S. Kim S.H. Effects of swimming exercise on serum irisin and bone FNDC5 in rat models of high-fat diet-induced osteoporosis J. Sports Sci. Med. 2019 18 596 603 31827343 176. Maalouf G.E. El Khoury D. Exercise-induced irisin, the fat browning myokine, as a potential anticancer agent J. Obes. 2019 2019 6561726 10.1155/2019/6561726 31065382 177. Kim H.J. So B. Choi M. Kang D. Song W. Resistance exercise training increases the expression of irisin concomitant with improvement of muscle function in aging mice and humans Exp. Gerontol. 2015 70 11 17 10.1016/j.exger.2015.07.006 26183690 178. Aydin S. Kuloglu T. Aydin S. Eren M.N. Celik A. Yilmaz M. Kalayci M. Sahin I. Gungor O. Gurel A. Cardiac, skeletal muscle and serum irisin responses to with or without water exercise in young and old male rats: Cardiac muscle produces more irisin than skeletal muscle Peptides 2014 52 68 73 10.1016/j.peptides.2013.11.024 24345335 179. Bubak M.P. Heesch M.W.S. Shute R.J. Dinan N.E. Laursen T.L. DT L.A.S. Slivka D.R. Irisin and fibronectin type III domain-containing 5 responses to exercise in different environmental conditions Int. J. Exerc. Sci. 2017 10 666 680 28966707 180. Fox J. Rioux B.V. Goulet E.D.B. Johanssen N.M. Swift D.L. Bouchard D.R. Loewen H. Senechal M. Effect of an acute exercise bout on immediate post-exercise irisin concentration in adults: A meta-analysis Scand. J. Med. Sci. Sports 2018 28 16 28 10.1111/sms.12904 28453881 181. Zhou X. Xu M. Bryant J.L. Ma J. Xu X. Exercise-induced myokine FNDC5/irisin functions in cardiovascular protection and intracerebral retrieval of synaptic plasticity Cell Biosci. 2019 9 32 10.1186/s13578-019-0294-y 30984367 182. Lourenco M.V. Frozza R.L. de Freitas G.B. Zhang H. Kincheski G.C. Ribeiro F.C. Goncalves R.A. Clarke J.R. Beckman D. Staniszewski A. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models Nat. Med. 2019 25 165 175 10.1038/s41591-018-0275-4 30617325 183. Ma E.B. Sahar N.E. Jeong M. Huh J.Y. Irisin exerts inhibitory effect on adipogenesis through regulation of Wnt signaling Front. Physiol. 2019 10 1085 10.3389/fphys.2019.01085 31507448 184. McPherron A.C. Lawler A.M. Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member Nature 1997 387 83 90 10.1038/387083a0 9139826 185. Sharma M. Kambadur R. Matthews K.G. Somers W.G. Devlin G.P. Conaglen J.V. Fowke P.J. Bass J.J. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct J. Cell. Physiol. 1999 180 1 9 10.1002/(SICI)1097-4652(199907)180:1<1::AID-JCP1>3.0.CO;2-V 10362012 186. Lee S.J. Lee Y.S. Zimmers T.A. Soleimani A. Matzuk M.M. Tsuchida K. Cohn R.D. Barton E.R. Regulation of muscle mass by follistatin and activins Mol. Endocrinol. 2010 24 1998 2008 10.1210/me.2010-0127 20810712 187. Gonzalez-Cadavid N.F. Taylor W.E. Yarasheski K. Sinha-Hikim I. Ma K. Ezzat S. Shen R. Lalani R. Asa S. Mamita M. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting Proc. Natl. Acad. Sci. USA 1998 95 14938 14943 10.1073/pnas.95.25.14938 9843994 188. Yarasheski K.E. Bhasin S. Sinha-Hikim I. Pak-Loduca J. Gonzalez-Cadavid N.F. Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting J. Nutr. Health Aging 2002 6 343 348 12474026 189. Walker K.S. Kambadur R. Sharma M. Smith H.K. Resistance training alters plasma myostatin but not IGF-1 in healthy men Med. Sci. Sports Exerc. 2004 36 787 793 10.1249/01.MSS.0000126384.04778.29 15126711 190. MacKenzie M.G. Hamilton D.L. Pepin M. Patton A. Baar K. Inhibition of myostatin signaling through notch activation following acute resistance exercise PLoS ONE 2013 8 e68743 10.1371/journal.pone.0068743 23844238 191. Matsakas A. Friedel A. Hertrampf T. Diel P. Short-term endurance training results in a muscle-specific decrease of myostatin mRNA content in the rat Acta Physiol. Scand. 2005 183 299 307 10.1111/j.1365-201X.2005.01406.x 15743390 192. Ko I.G. Jeong J.W. Kim Y.H. Jee Y.S. Kim S.E. Kim S.H. Jin J.J. Kim C.J. Chung K.J. Aerobic exercise affects myostatin expression in aged rat skeletal muscles: A possibility of antiaging effects of aerobic exercise related with pelvic floor muscle and urethral rhabdosphincter Int. Neurourol. J. 2014 18 77 85 10.5213/inj.2014.18.2.77 24987560 193. Hittel D.S. Axelson M. Sarna N. Shearer J. Huffman K.M. Kraus W.E. Myostatin decreases with aerobic exercise and associates with insulin resistance Med. Sci. Sports Exerc. 2010 42 2023 2029 10.1249/MSS.0b013e3181e0b9a8 20386333 194. Ryan A.S. Li G. Blumenthal J.B. Ortmeyer H.K. Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults Obesity 2013 21 1350 1356 10.1002/oby.20216 23687104 195. Lenk K. Schur R. Linke A. Erbs S. Matsumoto Y. Adams V. Schuler G. Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model Eur. J. Heart Fail. 2009 11 342 348 10.1093/eurjhf/hfp020 19218333 196. Lenk K. Erbs S. Hollriegel R. Beck E. Linke A. Gielen S. Winkler S.M. Sandri M. Hambrecht R. Schuler G. Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure Eur. J. Prev. Cardiol. 2012 19 404 411 10.1177/1741826711402735 21450574 197. Zhang L. Rajan V. Lin E. Hu Z. Han H.Q. Zhou X. Song Y. Min H. Wang X. Du J. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease FASEB J. 2011 25 1653 1663 10.1096/fj.10-176917 21282204 198. Zhou Y. Hellberg M. Hellmark T. Hoglund P. Clyne N. Muscle mass and plasma myostatin after exercise training: A substudy of Renal Exercise (RENEXC)-a randomized controlled trial Nephrol. Dial. Transplant. 2019 10.1093/ndt/gfz210 199. Baati N. Feillet-Coudray C. Fouret G. Vernus B. Goustard B. Jollet M. Bertrand-Gaday C. Coudray C. Lecomte J. Bonnieu A. New evidence of exercise training benefits in myostatin-deficient mice: Effect on lipidomic abnormalities Biochem. Biophys. Res. Commun. 2019 516 89 95 10.1016/j.bbrc.2019.06.014 31200956 200. Welle S. Bhatt K. Shah B. Thornton C. Insulin-like growth factor-1 and myostatin mRNA expression in muscle: Comparison between 62–77 and 21–31 yr old men Exp. Gerontol. 2002 37 833 839 10.1016/S0531-5565(02)00025-6 12175483 201. Baumann A.P. Ibebunjo C. Grasser W.A. Paralkar V.M. Myostatin expression in age and denervation-induced skeletal muscle atrophy J. Musculoskelet. Neuronal Interact. 2003 3 8 16 15758361 202. Schafer M.J. Atkinson E.J. Vanderboom P.M. Kotajarvi B. White T.A. Moore M.M. Bruce C.J. Greason K.L. Suri R.M. Khosla S. Quantification of GDF11 and myostatin in human aging and cardiovascular disease Cell Metab. 2016 23 1207 1215 10.1016/j.cmet.2016.05.023 27304512 203. Peng L.N. Lee W.J. Liu L.K. Lin M.H. Chen L.K. Healthy community-living older men differ from women in associations between myostatin levels and skeletal muscle mass J. Cachexia Sarcopenia Muscle 2018 9 635 642 10.1002/jcsm.12302 29654636 204. Hunger C. Odemis V. Engele J. Expression and function of the SDF-1 chemokine receptors CXCR4 and CXCR7 during mouse limb muscle development and regeneration Exp. Cell Res. 2012 318 2178 2190 10.1016/j.yexcr.2012.06.020 22766125 205. Tashiro K. Tada H. Heilker R. Shirozu M. Nakano T. Honjo T. Signal sequence trap: A cloning strategy for secreted proteins and type I membrane proteins Science 1993 261 600 603 10.1126/science.8342023 8342023 206. Bleul C.C. Farzan M. Choe H. Parolin C. Clark-Lewis I. Sodroski J. Springer T.A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry Nature 1996 382 829 833 10.1038/382829a0 8752280 207. Adlere I. Caspar B. Arimont M. Dekkers S. Visser K. Stuijt J. de Graaf C. Stocks M. Kellam B. Briddon S. Modulators of CXCR4 and CXCR7/ACKR3 Function Mol. Pharmacol. 2019 96 737 752 10.1124/mol.119.117663 31548340 208. Nagasawa T. Kikutani H. Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor Proc. Natl. Acad. Sci. USA 1994 91 2305 2309 10.1073/pnas.91.6.2305 8134392 209. Shirozu M. Nakano T. Inazawa J. Tashiro K. Tada H. Shinohara T. Honjo T. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene Genomics 1995 28 495 500 10.1006/geno.1995.1180 7490086 210. Vasyutina E. Stebler J. Brand-Saberi B. Schulz S. Raz E. Birchmeier C. CXCR4 and Gab1 cooperate to control the development of migrating muscle progenitor cells Genes Dev. 2005 19 2187 2198 10.1101/gad.346205 16166380 211. Brzoska E. Kowalewska M. Markowska-Zagrajek A. Kowalski K. Archacka K. Zimowska M. Grabowska I. Czerwinska A.M. Czarnecka-Gora M. Streminska W. Sdf-1 (CXCL12) improves skeletal muscle regeneration via the mobilisation of Cxcr4 and CD34 expressing cells Biol. Cell 2012 104 722 737 10.1111/boc.201200022 22978573 212. Bobadilla M. Sainz N. Abizanda G. Orbe J. Rodriguez J.A. Paramo J.A. Prosper F. Perez-Ruiz A. The CXCR4/SDF1 axis improves muscle regeneration through MMP-10 activity Stem Cells Dev. 2014 23 1417 1427 10.1089/scd.2013.0491 24548137 213. Parachikova A. Cotman C.W. Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease Neurobiol. Dis. 2007 28 143 153 10.1016/j.nbd.2007.07.001 17764962 214. Yoon J.E. Kim Y. Kwon S. Kim M. Kim Y.H. Kim J.H. Park T.J. Kang H.Y. Senescent fibroblasts drive ageing pigmentation: A potential therapeutic target for senile lentigo Theranostics 2018 8 4620 4632 10.7150/thno.26975 30279727 215. Nishiguchi M.A. Spencer C.A. Leung D.H. Leung T.H. Aging suppresses skin-derived circulating SDF1 to promote full-thickness tissue regeneration Cell Rep. 2018 24 3383 3392.e5 10.1016/j.celrep.2018.08.054 30257200 216. Periyasamy-Thandavan S. Burke J. Mendhe B. Kondrikova G. Kolhe R. Hunter M. Isales C.M. Hamrick M.W. Hill W.D. Fulzele S. MicroRNA-141-3p negatively modulates SDF-1 expression in age-dependent pathophysiology of human and murine bone marrow stromal cells J. Gerontol. A Biol. Sci. Med. Sci. 2019 74 1368 1374 10.1093/gerona/gly186 31505568 217. Wang J.S. Lee M.Y. Lien H.Y. Weng T.P. Hypoxic exercise training improves cardiac/muscular hemodynamics and is associated with modulated circulating progenitor cells in sedentary men Int. J. Cardiol. 2014 170 315 323 10.1016/j.ijcard.2013.11.005 24286591 218. Emmons R. Niemiro G.M. Owolabi O. De Lisio M. Acute exercise mobilizes hematopoietic stem and progenitor cells and alters the mesenchymal stromal cell secretome J. Appl. Physiol. 2016 120 624 632 10.1152/japplphysiol.00925.2015 26744505 219. Puchert M. Adams V. Linke A. Engele J. Evidence for the involvement of the CXCL12 system in the adaptation of skeletal muscles to physical exercise Cell Signal. 2016 28 1205 1215 10.1016/j.cellsig.2016.05.019 27237374 220. Yamada M. Hokazono C. Tokizawa K. Marui S. Iwata M. Lira V.A. Suzuki K. Miura S. Nagashima K. Okutsu M. Muscle-derived SDF-1alpha/CXCL12 modulates endothelial cell proliferation but not exercise training-induced angiogenesis Am. J. Physiol. Regul. Integr. Comp. Physiol. 2019 317 R770 R779 10.1152/ajpregu.00155.2019 31577158 221. Buckbinder L. Talbott R. Seizinger B.R. Kley N. Gene regulation by temperature-sensitive p53 mutants: Identification of p53 response genes Proc. Natl. Acad. Sci. USA 1994 91 10640 10644 10.1073/pnas.91.22.10640 7938006 222. Velasco-Miguel S. Buckbinder L. Jean P. Gelbert L. Talbott R. Laidlaw J. Seizinger B. Kley N. PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes Oncogene 1999 18 127 137 10.1038/sj.onc.1202274 9926927 223. Parmigiani A. Budanov A.V. Sensing the environment through sestrins: Implications for cellular metabolism International Review of Cell and Molecular Biology Academic Press Cambridge, MA, USA 2016 Volume 327 1 42 10.1016/bs.ircmb.2016.05.003 224. Lee J.H. Budanov A.V. Karin M. Sestrins orchestrate cellular metabolism to attenuate aging Cell Metab. 2013 18 792 801 10.1016/j.cmet.2013.08.018 24055102 225. Lee J.H. Bodmer R. Bier E. Karin M. Sestrins at the crossroad between stress and aging Aging 2010 2 369 374 10.18632/aging.100157 20606249 226. Lenhare L. Crisol B.M. Silva V.R.R. Katashima C.K. Cordeiro A.V. Pereira K.D. Luchessi A.D. da Silva A.S.R. Cintra D.E. Moura L.P. Physical exercise increases Sestrin 2 protein levels and induces autophagy in the skeletal muscle of old mice Exp. Gerontol. 2017 97 17 21 10.1016/j.exger.2017.07.009 28729213 227. Quan N. Sun W. Wang L. Chen X. Bogan J.S. Zhou X. Cates C. Liu Q. Zheng Y. Li J. Sestrin2 prevents age-related intolerance to ischemia and reperfusion injury by modulating substrate metabolism FASEB J. 2017 31 4153 4167 10.1096/fj.201700063R 28592638 228. Zeng N. D’Souza R.F. Mitchell C.J. Cameron-Smith D. Sestrins are differentially expressed with age in the skeletal muscle of men: A cross-sectional analysis Exp. Gerontol. 2018 110 23 34 10.1016/j.exger.2018.05.006 29751091 229. Rai N. Venugopalan G. Pradhan R. Ambastha A. Upadhyay A.D. Dwivedi S. Dey A.B. Dey S. Exploration of novel anti-oxidant protein sestrin in frailty syndrome in elderly Aging Dis. 2018 9 220 227 10.14336/AD.2017.0423 29896412 230. Budanov A.V. Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling Antioxid. Redox Signal. 2011 15 1679 1690 10.1089/ars.2010.3530 20712410 231. Crisol B.M. Lenhare L. Gaspar R.S. Gaspar R.C. Munoz V.R. da Silva A.S.R. Cintra D.E. de Moura L.P. Pauli J.R. Ropelle E.R. The role of physical exercise on Sestrin1 and 2 accumulations in the skeletal muscle of mice Life Sci. 2018 194 98 103 10.1016/j.lfs.2017.12.023 29273527 232. Zeng N. D’Souza R.F. Figueiredo V.C. Markworth J.F. Roberts L.A. Peake J.M. Mitchell C.J. Cameron-Smith D. Acute resistance exercise induces Sestrin2 phosphorylation and p62 dephosphorylation in human skeletal muscle Physiol. Rep. 2017 5 e13526 10.14814/phy2.13526 29263116 233. Liu X. Niu Y. Yuan H. Huang J. Fu L. AMPK binds to Sestrins and mediates the effect of exercise to increase insulin-sensitivity through autophagy Metabolism 2015 64 658 665 10.1016/j.metabol.2015.01.015 25672217 234. Cordani M. Sanchez-Alvarez M. Strippoli R. Bazhin A.V. Donadelli M. Sestrins at the interface of ROS control and autophagy regulation in health and disease Oxid. Med. Cell. Longev. 2019 2019 1283075 10.1155/2019/1283075 31205582 235. Kim M. Sujkowski A. Namkoong S. Gu B. Cobb T. Kim B. Kowalsky A.H. Cho C.S. Semple I. Ro S.H. Sestrins are evolutionarily conserved mediators of exercise benefits Nat. Commun. 2020 11 190 10.1038/s41467-019-13442-5 31929512 236. Villarreal X.C. Mann K.G. Long G.L. Structure of human osteonectin based upon analysis of cDNA and genomic sequences Biochemistry 1989 28 6483 6491 10.1021/bi00441a049 2790009 237. Bassuk J.A. Baneyx F. Vernon R.B. Funk S.E. Sage E.H. Expression of biologically active human SPARC in Escherichia coli Arch. Biochem. Biophys. 1996 325 8 19 10.1006/abbi.1996.0002 8554346 238. Mok S.C. Chan W.Y. Wong K.K. Muto M.G. Berkowitz R.S. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells Oncogene 1996 12 1895 1901 8649850 239. Brekken R.A. Sage E.H. SPARC, a matricellular protein: At the crossroads of cell-matrix communication Matrix Biol. 2001 19 816 827 10.1016/S0945-053X(00)00133-5 11223341 240. Kos K. Wilding J.P. SPARC: A key player in the pathologies associated with obesity and diabetes Nat. Rev. Endocrinol. 2010 6 225 235 10.1038/nrendo.2010.18 20195270 241. Aoi W. Naito Y. Takagi T. Tanimura Y. Takanami Y. Kawai Y. Sakuma K. Hang L.P. Mizushima K. Hirai Y. A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise Gut 2013 62 882 889 10.1136/gutjnl-2011-300776 22851666 242. Nakamura K. Nakano S. Miyoshi T. Yamanouchi K. Matsuwaki T. Nishihara M. Age-related resistance of skeletal muscle-derived progenitor cells to SPARC may explain a shift from myogenesis to adipogenesis Aging 2012 4 40 48 10.18632/aging.100426 22289652 243. Nakamura K. Nakano S. Miyoshi T. Yamanouchi K. Nishihara M. Loss of SPARC in mouse skeletal muscle causes myofiber atrophy Muscle Nerve 2013 48 791 799 10.1002/mus.23822 23424163 244. Nakamura K. Yamanouchi K. Nishihara M. Secreted protein acidic and rich in cysteine internalization and its age-related alterations in skeletal muscle progenitor cells Aging Cell 2014 13 175 184 10.1111/acel.12168 24245505 245. Jorgensen L.H. Jepsen P.L. Boysen A. Dalgaard L.B. Hvid L.G. Ortenblad N. Ravn D. Sellathurai J. Moller-Jensen J. Lochmuller H. SPARC interacts with actin in skeletal muscle in vitro and in vivo Am. J. Pathol. 2017 187 457 474 10.1016/j.ajpath.2016.10.013 27908613 246. Catoire M. Mensink M. Kalkhoven E. Schrauwen P. Kersten S. Identification of human exercise-induced myokines using secretome analysis Physiol. Genom. 2014 46 256 267 10.1152/physiolgenomics.00174.2013 247. Tai I.T. Tang M.J. SPARC in cancer biology: Its role in cancer progression and potential for therapy Drug Resist. Updat. 2008 11 231 246 10.1016/j.drup.2008.08.005 18849185 248. Tai I.T. Dai M. Owen D.A. Chen L.B. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy J. Clin. Investig. 2005 115 1492 1502 10.1172/JCI23002 15902309 249. Songsorn P. Ruffino J. Vollaard N.B. No effect of acute and chronic supramaximal exercise on circulating levels of the myokine SPARC Eur. J. Sport Sci. 2017 17 447 452 10.1080/17461391.2016.1266392 27996694 250. Said N. Frierson H.F. Jr. Chernauskas D. Conaway M. Motamed K. Theodorescu D. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression Oncogene 2009 28 3487 3498 10.1038/onc.2009.205 19597474 251. Senger D.R. Galli S.J. Dvorak A.M. Perruzzi C.A. Harvey V.S. Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 1983 219 983 985 10.1126/science.6823562 6823562 252. Leung D.W. Cachianes G. Kuang W.J. Goeddel D.V. Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen Science 1989 246 1306 1309 10.1126/science.2479986 2479986 253. Achen M.G. Stacker S.A. The vascular endothelial growth factor family; proteins which guide the development of the vasculature Int. J. Exp. Pathol. 1998 79 255 265 10.1046/j.1365-2613.1998.700404.x 10193309 254. Vital T.M. Stein A.M. de Melo Coelho F.G. Arantes F.J. Teodorov E. Santos-Galduroz R.F. Physical exercise and vascular endothelial growth factor (VEGF) in elderly: A systematic review Arch. Gerontol. Geriatr. 2014 59 234 239 10.1016/j.archger.2014.04.011 24856646 255. Ahluwalia A. Jones M.K. Szabo S. Tarnawski A.S. Aging impairs transcriptional regulation of vascular endothelial growth factor in human microvascular endothelial cells: Implications for angiogenesis and cell survival J. Physiol. Pharmacol. 2014 65 209 215 24781730 256. Ryan N.A. Zwetsloot K.A. Westerkamp L.M. Hickner R.C. Pofahl W.E. Gavin T.P. Lower skeletal muscle capillarization and VEGF expression in aged vs. young men J. Appl. Physiol. 2006 100 178 185 10.1152/japplphysiol.00827.2005 16166239 257. Olfert I.M. Howlett R.A. Tang K. Dalton N.D. Gu Y. Peterson K.L. Wagner P.D. Breen E.C. Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice J. Physiol. 2009 587 1755 1767 10.1113/jphysiol.2008.164384 19237429 258. Gustafsson T. Bodin K. Sylven C. Gordon A. Tyni-Lenne R. Jansson E. Increased expression of VEGF following exercise training in patients with heart failure Eur. J. Clin. Investig. 2001 31 362 366 10.1046/j.1365-2362.2001.00816.x 11298785 259. Ohno H. Shirato K. Sakurai T. Ogasawara J. Sumitani Y. Sato S. Imaizumi K. Ishida H. Kizaki T. Effect of exercise on HIF-1 and VEGF signaling J. Phys. Fit. Sports Med. 2012 1 5 16 10.7600/jpfsm.1.5 260. Rich B. Scadeng M. Yamaguchi M. Wagner P.D. Breen E.C. Skeletal myofiber vascular endothelial growth factor is required for the exercise training-induced increase in dentate gyrus neuronal precursor cells J. Physiol. 2017 595 5931 5943 10.1113/JP273994 28597506 261. Samitz G. Egger M. Zwahlen M. Domains of physical activity and all-cause mortality: Systematic review and dose-response meta-analysis of cohort studies Int. J. Epidemiol. 2011 40 1382 1400 10.1093/ije/dyr112 22039197 262. Katzmarzyk P.T. Janssen I. Ardern C.I. Physical inactivity, excess adiposity and premature mortality Obes. Rev. 2003 4 257 290 10.1046/j.1467-789X.2003.00120.x 14649376 263. Taylor A.H. Cable N.T. Faulkner G. Hillsdon M. Narici M. Van Der Bij A.K. Physical activity and older adults: A review of health benefits and the effectiveness of interventions J. Sports Sci. 2004 22 703 725 10.1080/02640410410001712421 15370483 264. Liposcki D.B. da Silva Nagata I.F. Silvano G.A. Zanella K. Schneider R.H. Influence of a Pilates exercise program on the quality of life of sedentary elderly people: A randomized clinical trial J. Bodyw. Mov. Ther. 2019 23 390 393 10.1016/j.jbmt.2018.02.007 31103125 265. Habchi H. Lorenzo-Villalba N. Andres E. Zulfiqar A.A. Physical activity among seniors: What benefits on geriatric criteria? Rev. Med. Liege 2020 75 89 93 32030932 266. Nuzum H. Stickel A. Corona M. Zeller M. Melrose R.J. Wilkins S.S. Potential benefits of physical activity in MCI and dementia Behav. Neurol. 2020 2020 7807856 10.1155/2020/7807856 32104516 267. Chen W.W. Zhang X. Huang W.J. Role of physical exercise in Alzheimer’s disease Biomed. Rep. 2016 4 403 407 10.3892/br.2016.607 27073621 268. Blondell S.J. Hammersley-Mather R. Veerman J.L. Does physical activity prevent cognitive decline and dementia? A systematic review and meta-analysis of longitudinal studies BMC Public Health 2014 14 510 10.1186/1471-2458-14-510 24885250 269. Moore S.C. Lee I.M. Weiderpass E. Campbell P.T. Sampson J.N. Kitahara C.M. Keadle S.K. Arem H. Berrington de Gonzalez A. Hartge P. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults JAMA Intern. Med. 2016 176 816 825 10.1001/jamainternmed.2016.1548 27183032 270. Heitmann B.L. Frederiksen P. Thigh circumference and risk of heart disease and premature death: Prospective cohort study BMJ 2009 339 b3292 10.1136/bmj.b3292 19729416 271. McCurdy A.P. Boule N.G. Sivak A. Davenport M.H. Effects of exercise on mild-to-moderate depressive symptoms in the postpartum period: A meta-analysis Obstet. Gynecol. 2017 129 1087 1097 10.1097/AOG.0000000000002053 28486363 272. Aarsland D. Sardahaee F.S. Anderssen S. Ballard C. Alzheimer’s Society Systematic Review Group Is physical activity a potential preventive factor for vascular dementia? A systematic review Aging Ment. Health 2010 14 386 395 10.1080/13607860903586136 20455113 273. Etgen T. Bickel H. Forstl H. Metabolic and endocrine factors in mild cognitive impairment Ageing Res. Rev. 2010 9 280 288 10.1016/j.arr.2010.01.003 20109582 274. Lautenschlager N.T. Cox K.L. Flicker L. Foster J.K. van Bockxmeer F.M. Xiao J. Greenop K.R. Almeida O.P. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: A randomized trial JAMA 2008 300 1027 1037 10.1001/jama.300.9.1027 18768414 275. Feskanich D. Willett W. Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women JAMA 2002 288 2300 2306 10.1001/jama.288.18.2300 12425707 276. Boone-Heinonen J. Evenson K.R. Taber D.R. Gordon-Larsen P. Walking for prevention of cardiovascular disease in men and women: A systematic review of observational studies Obes. Rev. 2009 10 204 217 10.1111/j.1467-789X.2008.00533.x 19207874 277. Ma D. Wu L. He Z. Effects of walking on the preservation of bone mineral density in perimenopausal and postmenopausal women: A systematic review and meta-analysis Menopause 2013 20 1216 1226 10.1097/GME.0000000000000100 24149921 278. Janssen I. Shepard D.S. Katzmarzyk P.T. Roubenoff R. The healthcare costs of sarcopenia in the United States J. Am. Geriatr. Soc. 2004 52 80 85 10.1111/j.1532-5415.2004.52014.x 14687319 279. Ray N.F. Chan J.K. Thamer M. Melton L.J. 3rd Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation J. Bone Miner. Res. 1997 12 24 35 10.1359/jbmr.1997.12.1.24 9240722